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CHAPTER 1: INTRODUCTION: FOLATES IN HUMAN HEALTH 
1.1 The identification and isolation of folate 
The functional importance of many essential vitamins and minerals, including Vitamin B9, 
folicin or folic acid, was unearthed by rigorous studies that examined associated pathologies that 
resulted from nutrient deficiencies.  The history of folates in human health originates in 
hematology.  At this time, investigating the impact of diet on human disease was emerging, with 
much emphasis being placed on what we now know as nutritional anemias.1,2  Macrocytic anemia, 
a subclass of megaloblastic anemia, was prevalent among pregnant women in impoverished 
communities whose access to proteins, vegetables and fruits was limited.1  This specific type of 
anemia is characterized by enlarged erythrocytes which is thought to be a product of impaired 
DNA synthesis in red blood cells; a cell type with a high rate of turnover.3,4  In observing the 
effects of diet in this condition on albino rats and monkeys, Dr. Lucy Wills and colleagues 
discovered that the administration of yeast, yeast extract ( Marmite™) or crude liver extract  to  
individuals subjected  to a diet deficient in B vitamins, ameliorated the anemic condition.1,2,5  This 
extrinsic factor contained in yeast was later called “Wills’ factors”  by Drs. Janet Watson and 
William B. Castle.  Through the examination of multiple case studies of macrocytic anemia  treated 
with different fractions of liver extract and beef muscle, Watson and Castle concluded that there 
was an additional component/ factor  present that was responsible for assuagement of marocytic 
anemia  that was different from that which cured Addisonian anemia (pernicious anemia).5,6  
Unbeknownst to the scientists of the time, yeast, plants and other microorganism are cable of de 
novo folate biosynthesis and the liver is the primary site of the body’s folate storage.7,8  Based on 
the empirical clinical data, there was an eruption of critical studies that examined the treatment 
potential of liver extract (given orally or parentally) in anemia, which in turn gave rise to multiple 
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names for folate, based solely on the animal used in the experiment.  These included M factor 
(monkeys), vitamin Bc (chickens), Lactobacillus casei factor, and anti-anemia factor, to name a 
few.  The nomenclature used to describe folic acid or folates has undergone many iterations with 
it being named pteroylglutamic acid due to the presence of a pteridine.  The current name, folic 
acid or folates, was not used until the 1940’s, upon isolation and identification of the compound 
in green leafy vegetation.1,5,9 
Folate was first isolated from spinach leaves in 1941 by Herschel Mitchell and colleagues and 
was eponymously named folic acid after the Latin word folium that translates to leaf.1,10,11  In 
1943, E. L. Robert Stokstad and colleagues isolated this very same “factor” from the liver that 
promoted the growth of Lactobacillus casei.1,12  Stokstad synthesized the first pure crystal form of 
the unconjugated compound, and from that, he was able to reveal important structural information 
about the molecule.  During his tenure at Berkley’s Nutritional Science department, Stokstad began 
seminal research on folic acid metabolism.  Stokstad’s research serves as the foundation for 
antifolate drug development as he identified many of the enzymes involved in the folate metabolic 
cycle nearly 34 years ago (1979).5  This early work was credited for leading to the development of 
the first antifolate, aminopterin (4-aminopteroic acid) (AMT). 
Today, folates are well recognized for the role they play in human health, growth and 
development.13  One of many well documented examples of the impact of folates on human health 
is the indisputable role that the vitamin plays in the full development and closure of the neural tube 
during days 21-28 post-conception or embryogenesis.14  Adequate folate supplementation in 
pregnant women has been thought to lead to the prevention of congenital malformations of the 
central nervous system and consequently a decrease in infant mortality and morbidity as neural 
tube defects (NTDs) are only second to cardiac defects as the most common congenital 
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malformations.15  The abundance of landmark studies that supported this notion lead to a  
mandatory implementation of folic acid fortification in grain products in the United States.15  The 
resulting rapid decline in infants born with spina bifida or anencephaly, as a consequence of neural 
tubes defects, demonstrated the importance of folate in early development.14,15  Moreover, 
deficiencies in this vitamin and mutations in genes associated with folate absorption and/or 
metabolism have been linked to other disease states and disorders such as vascular disease, certain 
subtypes of cancer and Alzheimer’s disease.4  This provided concrete evidence that folates were 
vital to the preservation of normal cellular physiology and were a critical component to human 
health. 
1.2 Folate biology and chemistry 
Many anabolic pathways require the addition or modification of carbon groups.  Folates are 
coenzymes that participate in the metabolism of amino acids and nucleotides by donating or 
transferring the required carbon units, which is referred to as one-carbon metabolism.9,13  Because 
folate metabolism plays an integral part in the movement of carbon, it has been described by many 
as the cornerstone of one-carbon metabolism.13,16,17  One-carbon metabolism is thought to be 
comprised of three distinct but interwoven metabolic cycles, the folate metabolic cycle, the 
methionine cycle and the trans-sulfuration pathway.18-20  The unifying feature of these three 
pathways is the transfer of active one carbon units in a number of enzymatic reactions. 
Folate is a generic term that describes any compound that participates in similar cellular 
activities as the vitamin that results in the production of amino acids, purine nucleotides and 
thymidylate.21,22  This includes naturally occurring folates in foodstuffs, enzymatically converted 
species and the synthetic derivative folic acid.21,22  The chemical name of the non-conjugated 
vitamin (containing a single γ glutamate residue) is pteroylmonoglutamate (PteGlu).17  This 
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molecule is comprised of three groups, including (1) a pterin moiety, which has a methylene group 
linage at the 6th position to a (2) para amino benzoyl group and (3) L-glutamatic acid.17  The 
pteridine ring is of great functional importance in the metabolism of this vitamin.  The two nitrogen 
atoms placed on the ring favors reduction product that leads to di and/or tetra hydrogenation of the 
ring (Figure 1.1). 
Folates destined for intracellular accumulation undergo extensive metabolism to assume their 
role as cofactors in physiological reactions.8,17,19  This metabolism is thought to principally involve 
the reduction of the pteridine ring (Figure 1.1) (which introduces an asymmetric center at the C6 
position), polyglutamylation (the successive addition of glutamate moieties to the γ-glutamyl of 
the parent molecule) and the transition to oxidative or reductive states.9,19,23,24  These reactions 
give rise to a number of active tetrahydrofolate (THF) forms that are distinguishable by the 
substituents they carry at the N5 or N10 positions.8  They can include methenyl (CH+), methylene 
(CH2), methyl (CH3), formyl groups (CHO) and formimino (CH=NH) (Figure 1.2).
8  The active 
tetrahydro forms are the only species that can readily donate or accept single carbons units.8,19  
Naturally occurring folates exist as reduced folylpolyglutamates when within the cell, in which 
there are multiple glutamate moieties attached to the γ-carboxyl end of the folate molecule.19,23  
The most prevalent form of folate identified in mammals is reduced 5-methyl tetrahydrofolate.25,26  
In contrast, the synthetic vitamin used in food fortification, folic acid, is fully oxidized and tends 
to be less labile than naturally occurring folates, which become less stable with oxidation.9  
Because of this, naturally occurring folates and folic acid have a different point of entry in the 
metabolic cycle. 
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Adapted open access figure, with permission of Carolyn Tam et al.27  Copyright (2012) 
“Circulating Unmetabolized Folic Acid: Relationship to Folate Status and Effect of 
Supplementation,” Obstetrics and Gynecology International, vol. 2012, Article ID 485179, 17 
pages, 2012. 
Figure 1.1: The reduction of folic acid.  Above is the structure of the folic acid, a synthetic 
derivative of naturally occurring forms found in legumes, green leafy vegetables and some fruits.  
Folic acid is comprised of three major groups including 1) pteridine 2) para benzoate and glutamic 
acid moieties.  Folic acid enters the folate metabolism cycle at the site of dihydrofolate reductase, 
which acts to reduce the pyrazine ring of the pteridine group resulting in a dihydrofolate form.  
This dihydrofolate undergoes an additional reduction through the same enzyme to produce the 
active tetrahydrofolate co-enzyme that participates in one-carbon metabolism. 
  
Folic acid is reduced by DHFR to produce the 
enzymatically active tetrahydrofolate species 
active tetrahydrofolate 
Pyrazine ring 
Folic  Acid 
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Adapted from Themedicalbiochemistrypage.org, Dr. Michael King copyright (1996-2014) 
Figure 1.2: Enzymatically active folate metabolites.  This figure highlights multiple forms of 
active folate derivatives.  Each metabolite differs in the oxidation state of the acquired substituent 
and the location of substituent.  These metabolites play distinct roles in folate metabolism which 
result cellular stores of serine, glycine, purines, methionine and thymidylate. 
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There are multiple enzymes and binding proteins involved in folate metabolism that act to 
regulate folate homeostasis in tissues through a complex system of feedback loops, substrate 
specificities and allosteric regulation.19  These reactions have a global impact on the cell by 
affecting both genomic and physiological aspects of function.15,28  The epicenters of folate 
mediated one-carbon metabolism reside in the cytoplasm, the mitochondria and the nucleus 
(Figure 1.5).17,29  Cytoplasmic one-carbon metabolism has been studied extensively with well-
documented and detailed studies exploring the mechanics of folate metabolism in this 
compartment.8,17,19  While our knowledge remains limited for both mitochondrial and nuclear 
folate metabolism, there is a growing surge of attention directed towards these two compartments 
with the hope of gaining a complete picture of the role of folates in cellular physiology.  The 
primary source for carbon units used in cytoplasmic one-carbon metabolism is believed to 
originate from the one-carbon metabolism that occurs in the mitochondria which is estimated to 
contain 40% of the total intracellular folates.20,25  While knowledge is limited on nuclear folate 
metabolism, studies with a radio-labeled folate precursor suggest that 10% of total cellular folates 
reside in the nucleus.20   
Upon cellular entry, naturally occurring folates derived from leafy materials in foodstuff 
exist as 5-methyl THF polyglutamates, but begin their journey across the cell membrane in the 
monoglutamate transport form.19,26  Mammalian serum/plasma contains folate conjugases/γ-
glutamyl hydrolases, which strip the once polyglutamylated vitamin of additional glutamates at 
the gamma carboxyl end of the molecule, resulting in mono-glutamylated folates in the blood and 
urine.19  Folates carry a slight negative charge due to ionization of the dicarboxcyclic acid tail, 
thereby requiring some form of transmembrane transport to gain intracellular entry.19,25,26  
Following intracellular translocation through a specified mechanism of folate transport, folates are 
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then subjected to polyglutamylation performed by the cytosolic enzyme folylpoly-gamma-
glutamate synthetase (FPGS).19  Polyglutamylation via FPGS was validated as an essential step in 
folate metabolism through the examination of the Chinese hamster ovary (CHO) cell lines that 
were auxotrophic for glycine, thymidine and purines, (CHO AUX B1 cells). 19,23  These cells were 
discovered to lack polyglutamylated folates due to the absence of FPGS activity, consequently 
resulting in a low intracellular folate pool.19,23  This provided evidence of a dependency or 
requirement for these cells to obtain products of folate metabolism/one carbon metabolism from 
exogenous sources.19,23  More recently, studies that investigated the anti-tumor activity of 
antifolates in cells with augmented human FPGS, reported that cells with increased expression of 
the FPGS protein showed enhanced sensitivities to antifolates.30,31  Alternatively, the loss of FPGS 
expression and/ or activity has been elucidated as a probable mechanism in antifolate resistance.32 
In addition to serving as a mechanism of cellular retention, polyglutamylation also aids in 
folate homeostasis by providing a layer of regulation by controlling substrate specificity.17  The 
step-wise addition of glutamates at the tail of intracellular folates by FPGS has been well 
documented.18,19  The extent of polyglutamylation that can differ among intracellular folates is 
thought to create competition with the lower or monoglutamylated species for which the affinity 
is higher when compared to extensively glutamylated species for which the Km has increased.18,19  
In general, increasing the length of the polyglutamate tail is associated with an increased affinity 
to enzymes involved in these pathways with the exception of DHFR.17  There is a clear correlation 
between affinity and polyglutamylation.  However there is a plateau or change in kinetics for the 
heptaglutamylated species, which is the predominant form in humans.19,33  Curiously, some of 
these highly glutamylated folate metabolic products can act as inhibitors towards other metabolic 
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enzymes within this pathway.17  This highlights the product-driven regulation of one-carbon 
metabolism that occurs within the folate cycle. 
Another important feature of polyglutamate tail is the role it plays in the “channeling” of 
substrate.17,34,35  Channeling is described as the sequential movement of substrate from one enzyme 
to another without exposure or release into the surrounding solvent.29,36  Channeling is thought to 
add an additional layer of regulation in one-carbon metabolism due to the formation of enzyme 
complexes necessary to produce the end product.20,34  Many investigators studying folate 
metabolism, more specifically the enzymology associated with this complex and sophisticated 
system, have proposed and supported the theory of the formation of a “metabolon” commonly 
referred to as the “purinosome”.29  The purinosome has been described as a dynamic multi–enzyme 
complex that forms in the cytoplasm during the G1 phase of the cell cycle that facilitates de novo 
purine synthesis.29  While metabolic compartmentalization in organelles has been suggested to 
serve as a regulatory mechanism, the temporal and spatial assembly of such multi-enzyme 
complexes plays a role in directing the activation these pathways.20  Folates with extended 
polyglutamyl tails are believed to participate in this distinct type of metabolic partitioning.19,34,37,38  
Experts postulate that such channeling evolved not only to increase the efficiency of this metabolic 
pathway but to also protect labile intermediates that would be rendered inactive due to extensive 
oxidation.19,20,34,36  With this in mind, when surveying enzyme activity within this pathway, in situ 
methods are more likely to accurately recapitulate the physiological picture as the channeling 
process will be uninterrupted and the natural abundance of multiple polyglutamylated species 
would be present. 
Intracellular polyglutamylated folate species are the primary molecules that are prepared 
to engage in cellular interactions with enzymes in one-carbon metabolism. 17  Many reviews on 
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one-carbon metabolism have separated these enzymes by their involvement in assorted pathways 
based on their functions and the organelles that house these reactions.  Fox and Stover created four 
distinct functional categories for these enzymes which include (i) one carbon generating enzymes, 
(ii) THF interconverting enzymes, (iii) THF-dependent biosynthetic enzymes and (iv) the non-
catalytic THF binding proteins.17  These enzymes can be further distinguished based on the 
organelle in which they performed their specialized metabolic function.  In general, the metabolic 
products formed in these reactions are not exchanged with other cellular compartments, which 
offers an explanation for the seemingly redundant existence of metabolic enzymes (or isozymes) 
in the mitochondria, cytoplasm and the nucleus (Figure 1.5).8 
There are a number of enzymes involved in the folate-dependent one-carbon metabolic 
cycle.  In this cycle, folate is used as a very versatile carrier molecule that can transfer activated 
one-carbon units of varying oxidation states from one metabolic reaction to the other.  These 
enzymes may be present in multiple isoforms with very specific roles that are determined by where 
they are compartmentalized and when they are expressed; this may vary with the stage of cell 
cycle, cell type and most interestingly, in normal versus cancer cells.17,34  The first enzyme that 
the naturally occurring folylpolyglutamate, 5-methyl THF, encounters is the cytoplasmic enzyme 
methionine synthase (MS).  This enzyme is characterized as a THF biosynthetic enzyme and acts 
to transfer the methyl group from 5-methyl THF to participate in the remethylation of 
homocysteine and the production of methionine.  The latter, upon adenylation, becomes the 
universal methyl donor, S-adenosylmethionine (SAM), which is responsible for a number of 
cellular methylation events.  In addition, this reaction also leads to the regeneration of the THF 
cofactor, which can now act as a carrier molecule and serve as a substrate for cytoplasmic serine 
hydroxymethyltransferase (SHMT).  Cytoplasmic SHMT is a one-carbon generating enzyme that 
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participates in the pyridoxal-5 phosphate- (PLP also known as vitamin B6) dependent reversible 
conversion of serine to glycine.17,39  In this reaction, the C3 of serine is transferred to THF, forming 
N5,N10 methylene THF and the resulting glycine product. 19,23  SHMT is appropriately regarded as 
the most critical enzyme in folate metabolism due to the importance of the metabolic product it 
yields, N5, N10-methylene THF, which serves as a substrate for multiple enzymes in this pathway. 
In the cell, SHMT exists as three isoforms with some overlapping functions.  The function 
of each isoform appears to be dictated by the organelle that houses the enzyme.  However, one 
feature that is common among the isoforms is the irreversible inhibition by 5-formyl THF 
(leucovorin) which acts to negatively regulate all isoforms, albeit to varying degrees.40  Studies 
have shown that the primary role for the cytoplasmic isoform, SHMT1, is to direct the cycle in the 
direction of glycine, resulting in the production of N5, N10-methylene THF for the production of 
thymidylate or thymidine monophosphate.41-43  The monophosphate is later converted into the tri-
phosphate form that serves to support DNA replication and repair as the pyrimidine nucleotide, 
thymidine triphosphate (dTTP).  However, depending on the cellular environment, N5,N10-
methylene THF can be converted into other metabolic products that could lead either to the 
remethylation of homocysteine or the de novo production of purine nucleotides. 
Limiting concentrations of N5,N10-methylene THF, in conjunction with the demand for this 
folate derivative in feeding multiple outputs in the metabolic pathways, creates competition and a 
requirement for intricate feedback regulation to prevent accumulation of metabolic products.  The 
interconnectedness of three metabolic cycles is clearly exemplified by the fate of N5,N10-
methylene THF  and the importance of the SHMT enzyme.  As previously mentioned, the folate 
derivative 5-methyl THF serves as the immediate substrate leading to the remethylation of 
homocysteine, resulting in methionine and consequently SAM production.  Elevated SAM 
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concentrations can lead to the inhibition of 5,10-methylene tetrahydrofolate reductase (MTHR), 
the enzyme responsible for the reduction of N5,N10-methylene THF to 5-methyl THF.8,17,19  In 
doing so, SAM regulates the folate cycle to allow cellular provisions for de novo nucleotide 
biosynthesis while maintaining homeostasis for the methionine cycle.42  Cytoplasmic SHMT has 
also been implicated in the regulation of the flux of this pathway that preferentially supplies N5, 
N10-methylene THF to TS by two proposed mechanisms: (1) acting as a folate binding protein and 
sequestering 5-methyl THF from the enzymatic activity of MS; and, (2) as the SHMT reaction is 
reversible, it can act to deplete the N5,N10-methylene THF pool to synthesize serine with the use 
of glycine, therefore preventing its conversion to 5-methyl THF by MTHR.17,42 
Additional validation of the important role of cytoplasmic SHMT role in the production of 
thymidylate is suggested by the binding of 5-formyl THF to cytosolic SHMT1.  Studies have 
suggested that this binding acts a regulatory switch to drive the pathway towards thymidylate 
synthesis instead of the remethylation of homocysteine.40,42  The mitochondrial SHMT2 isoform 
is believed to be involved in the conversion of serine to glycine and is ubiquitously expressed 
(thought to be responsible for the majority of the glycine content in cells).  The cytoplasmic 
isoform is predominately found in the kidney and liver where it is not as active in the serine to 
glycine conversion.  It facilitates the reversible interconversion of serine and glycine while forming 
5,10 methylene THF.44 
Serving as one of the most critical components of this pathway, 5, 10-methylene THF is 
principally involved in the methylation of dUMP to dTMP in thymidylate formation catalyzed by 
TS.26  Dihydrofolate is the by-product of this reaction, which is converted to THF by dihydrofolate 
reductase (DHFR).  THF can be metabolized to promote an additional revolution in this cycle.  
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Synthetic folic acid supplements also act to generate THF when reduced to the di- then 
tetrahydrofolate cofactor form by DHFR. 
In addition to participating in thymidylate formation, 5, 10-methylene THF can be reduced 
to 5-methylTHF by MTHR.  THF can be converted into 10-formyl THF by mitochondria-derived 
formate and cytosolic ATP.  This enzyme is also responsible for the irreversible conversion of 5, 
10-methenyl THF to 5- formyl-THF. 
Both the mitochondrial isozyme SHMT2, and cytoplasmic enzyme SHMT1 play a critical 
roles in one-carbon metabolism through the production of active one-carbon units and the 
production of serine, glycine and formate that can also serve as carbon donors for other reactions.  
Interestingly, compartmentalization of these enzymes determines the fate of the newly formed 
product, 5,10-methyleneTHF (Figure 1.5).20  Radioactive isotope tracing experiments provided 
evidence that cytoplasmic SHMT (SHMT1) produces this substrate for the transmethylation of 
dUMP, performed by the cytoplasmic and nuclear TS.45 
Both in vivo and in vitro studies have identified the SHMT conversion of THF to 5, 10-
methylene THF as the rate-limiting step in thymidylate synthesis.  In vitro studies with SHMT -/- 
null mice show a near 75% reduction in TS activity in isolated nuclei.46,47  The abundance of 
NADPH/NADP+ supports a reductive cytoplasmic space that makes the conversion of 5,10-
methylene THF to 10-formylTHF highly unlikely; therefore the cytoplasmic supply of  5,10-
methylene THF does not support the purine biosynthetic pathway.17  Rather, as demonstrated by 
previous observations of SHMT1, the cytoplasmic isozyme is principally involved in the 
production of 5,10-methylene THF to support thymidylate synthesis.42  There is research that 
demonstrates the unique role of mitochondrial SHMT2 function, which is distinguishable from its 
cytoplasmic counter parts, SHMT1 and SHMT2α.17,40 
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Mitochodrial folate metabolism 
Conjugated folates cannot be transported into the mitochondria, as polyglutamylated 
species are not substrates for the mitochondrial folate transporter (MFT), solute carrier family 
member SLC25A32.19,20 However, the shared affinity for monoglutamylated folate forms between 
MFT and folypolyglutamate synthase creates competition among these two proteins in the 
cytoplasm.19  Monoglutamate forms of folates that successfully enter the mitochondria generate a 
distinct folate pool that is maintained within the organelle.20  The mitochondria serves as an 
important source of cytoplasmic carbon, glycine and formate.48  Mitochondrial formate is a product 
of serine, glycine, dimethylglycine, sarcosine and choline catabolism.8  SHMT2 provides carbon, 
glycine and formate to participate in cytoplasmic biosynthetic reactions offered by the 
mitochondrial metabolism of serine.8  The glycine autotrophic CHO cell line clearly illustrates the 
independence of function of the cytoplasmic and mitochondrial SHMT isozymes.19  
Additional sources of 5, 10-methylene THF include the glycine cleavage system, which is 
a multi-enzyme system that participates in the oxidation of glycine into 5, 10-methylene THF, CO2 
and ammonia.8  This system is thought to produce 40% of glycine flux, with the one carbon units 
produced from this system contributing to purine and thymidylate biosyntheses that occur in the 
cytoplasm.8   
De novo purine biosythesis 
The de novo purine nucleotide biosynthetic pathway is a multi-step enzymatic process that 
yields IMP from the initial starting product phosphoribosyl pyrophosphate (PRPP).  The numbered 
reactions shown in Figure 1.3 are catalyzed by the following monofunctional enzymes: 1, 
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glutamine phosphoribosylpyrophosphate amidotransferase (GPAT); 4, formylglycinamide 
ribonucleotide synthase (FGAM synthetase); and 8, adenylosuccinate lyase (ASL).  Reactions 2, 
3 and 5 are catalyzed by the trifunctional glycinamide ribonucleotide (GAR) formyltransferase 
(GARFTase) which contains GAR synthase (GARS; reaction 2), GAR formyltransferase 
(GARFTase; reaction 3) and 5-aminoimidazole ribonucleotide synthase (AIRS; reaction 5) 
activities.  Reactions 6 and 7 are catalyzed by the bifunctional phosphoribosylaminoimidazole 
carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) enzyme, 
which contains carboxyaminoimidazole ribonucleotide synthase (CAIRS; reaction 6) and 5-
aminoimidazole-4-(N-succinylocarboxamide ribonucleotide synthase (SAICARS; reaction 7) 
activities.  Reactions 9 and 10 are catalyzed by a bifunctional enzyme, 5-aminoimidazole-4-
carboxamide (AICA) ribonucleotide (AICAR) formyltransferase (AICARFTase)/IMP 
cyclohydrolase (ATIC) that catalyzes the last two steps in the pathway for de novo synthesis of 
IMP.  Folate-dependent reactions (reactions 3 and 9) in which 10-formyl THF serves as the one-
carbon donor are catalyzed by GARFTase and AICARFTase.  AICA and AICAR can be 
metabolized to AICAR monophosphate (ZMP) by either adenine phosphoribosyl transferase 
(APRT) or adenosine kinase (AK), thus circumventing the reaction catalyzed by GARFTase.  The 
activation of AMPK that results in inhibition of mTOR is also depicted. 
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Reprinted with the permission of Mitchell-Ryan et al. (2013) Copyright. J Med Chem 
 
Figure 1.3: De novo purine biosynthesis.  The activated ribose PRPP, the phosphorylated product 
of the pentose phosphate pathway, is systematically converted into the purine precursor IMP in a 
10 step process.  Folate-dependent steps 3 and 9 are initiated by the enzymes GARFTase and 
AICARFTase, respectively.  In addition to the de novo production of purine nucleotides, this 
pathway also provides metabolic intermediates (i.e., AICAR (ZMP)) that can activate signal 
transduction pathways that are responsive to cellular energetics which function to modulate cell 
survival via AMPK activation and mTOR inhibition. 
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GARFTase and AICARFTase are two cytoplasmic enzymes involved in de novo purine 
synthesis.  These folate-dependent enzymes work to generate inosine monophosphate (IMP), a 
purine precursor that can be further metabolized to guanosine and adenosine nucleotides.  There 
are two pathways responsible for intracellular purines, the de novo purine pathway and salvage 
pathways (Figures 1.3 and 1.4).  Most often, normal cells that possess intact machinery for the 
salvage pathway will undergo this energy efficient method that uses preformed bases from 
degraded and metabolized purines that are recycled into nucleotides for the use in DNA 
synthesis.49  The process of cellular transformation introduces chromosomal abnormalities that 
include deletions in chromosomal segments that house tumor suppressor genes.  One common 
deletion involves chromosome 9, and is reported to include the chromosome 9p21 locus of 
multifunctional tumors suppressors, p14ink4a, p15ink4b and p16ARF.50,51  Methylthioadenosine 
phosphorylase (MTAP), an essential enzyme in the purine salvage pathway that is often co-deleted 
with other well-established aforementioned tumor suppressors located on chromosome 9.46,47  
Tumors that harbor this deletion lack the capacity to use this purine salvage pathway as a source 
of purines and are heavily dependent upon the de novo purine biosynthetic pathway to support the 
high demand for purine nucleotides and carbon backbones in aberrant cell division.46,47 
There is some debate over the folate metabolite(s) that acts as a coenzyme for purine 
biosynthetic reactions.  Earlier studies proposed 10-formyl THF as the sole cofactor associated 
with the conversion of GAR and AICAR to their respective formylated species formyl glycinamide 
ribonucleotide (FGAR) and formyl 5-aminoimidazole-4-carboxamide ribonucleotide of 
(FAICAR), driven by  GARFTase and AICARFTase.8,17  However, more recent studies suggest 
that 10-formyl dihydrofolate not only plays a part in the activation of these enzymes but is the 
preferred substrate for AICARFTase.52,53 
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Adapted open access figure with the permission of  Lubin M, Lubin A (2009) Selective Killing of 
Tumors Deficient in Methylthioadenosine Phosphorylase: A Novel Strategy. PLoS ONE 4(5): 
e5735 
 
Figure 1.4: The purine salvage pathway and cellular products.  MTAP is an essential enzyme 
in the purine salvage pathway, producing both 5’-deoxymethylthioribose-1-phosphate (MTR-1-P) 
and the adenine free base.  Through APRT, adenine can be converted into AMP and later into ATP 
following phosphorylation events, thereby aiding in cellular energetics.  Deoxyribose AMP 
(dAMP) can be converted into the purine nucleotide adenosine, which can incorporated into DNA 
during replication and DNA damage repair.  Through a multistep process, MTR-1-P is converted 
into Methionine, that can go on to assist in protein synthesis.  The loss of MTAP would leave the 
cell dependent upon de novo purine synthesis for adenosine nucleotides, and therefore DNA 
replication. 
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Nuclear folate metabolism 
An increasing number of studies have described a type of folate metabolism that occurs in 
the nucleus.  This is thought to arise from the nuclear translocation of SHMT2α (which has a 
redundant role in both the cytoplasm and the nucleus), TS and DHFR, which form a multi-enzyme 
complex to facilitate nuclear thymidylate synthesis.47  The purported significance of this 
physiological event is to maintain genomic integrity in DNA replication and repair (as this has 
been cited to occur during S, G2/M and during damage to DNA from UV exposure), in addition 
to preventing the mis-incorporation of uracil.45,47  This also holds particular significance in the 
prevention of uracil accumulation, which also plays a part in compromising genomic integrity.45  
Further, in vitro studies have substantiated these observations by indicating that nuclear membrane 
disruption (via sonication) resulted in nuclei that failed to possess de novo TS activity.45 
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Adapted with permission of Fox et al.17 Copyright (2008) Vitamins and Hormones. Ch. 1 
Figure 1.5: The compartmentalization of folate metabolism.  Folate metabolism can occur in 
three compartments with the cell, the mitochondria, the nucleus and the cytoplasm.  Not much is 
known about nuclear folate metabolism, however, it is thought to play an important role in 
thymidylate synthesis.  Folate pools in the cytoplasm and the mitochondrial are not 
interchangeable.  The mitochondrial formate combines with cytoplasmic THF to produce the folate 
cofactor essential for de novo purine synthesis. 
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1.3 Folate tissue absorption 
Mammals must acquire preformed folates from the diet due to an inability to synthesize 
these water–soluble vitamins de novo.  Dark green leafy vegetables and select fruits are notable 
high sources of the vitamin.  Intracellular accumulation of folates is predominately performed by 
transmembrane carriers/transporters and receptors.  Tissue accumulation of folate is dictated by 
the expression of transporters/carriers that permit the influx of folates, polyglutamylation at the γ 
glutamate on the carboxyl end of the parent molecule and expression or ability for exporter proteins 
to bind folate and contribute to their efflux from cells.   
The mechanisms of folate transport have been evolutionary conserved over many millions 
of years.  The existence of the two solute carrier (SLC) family members that participate in folate 
transport, SLC19A1 (reduced folate carrier or RFC) and SLC46A1 (proton coupled folate 
transporter or PCFT) date back to the Vendian period (approximately 523-543 million years ago).15  
Genes of both transporters have been identified in Pseudocoelomata, more specifically 
C.elegans.15  Folate receptor genes evolved much later and made their first appearance in 
chordates.15  Salbaum and colleagues speculate that folate receptors (FRs), with their superior 
binding affinities, evolved to ensure genomic stability and to preserve DNA methylation patterns 
even when folate supplies were limited.15  Folate availability is an important factor in modulating 
the expression levels for each of the three proteins.  A number of studies have confirmed that low 
concentrations of folates lead to increased expression of intestinal RFC and PFCT.54-57  Much like 
RFC and PCFT, FR alpha mRNA transcripts and protein expression is increased under folate-
deficient conditions.58-63  Cancer is one of many disease states that can result in a decrease in serum 
folate levels due to the increased demand for folate cofactors to participate in DNA replication for 
rapidly dividing cells.64  Interestingly, patients with FRα positive tumors, like ovarian cancer, have 
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increased levels of FRα protein in their serum.65-67  Due to this elevation, serum FRα levels have 
been considered as a plausible biomarker to detect epithelial ovarian cancer.65,66   
The Reduced Folate Carrier (RFC;SLC19A1) 
The RFC, as its name suggests, is a facilitative transmembrane transporter with a very high 
affinity for reduced folates (Km: 1-3µM), e.g 5-methyl-THF.25  The RFC protein is comprised of 
591 amino acids and has a molecular mass of approximately 65 kDa (Figure 1.6).25,68  Due to 
pronounced glycosylation at residue Asn 58, the molecular weight of the modified protein is 
~85kDa, a ~20 kDa difference from the original molecular weight of ~65 kDa.25,69  The human 
RFC gene is located on chromosome 21q22.2 and is reported to be regulated by a host of regulatory 
proteins and transcriptional start sites.70  The very complex transcriptional regulation of RFC is 
carried out by six non-coding exons with multiple promoters and with the aid of multiple 
transcription factors from various families.71,72  RFC has been described by Whetstine and 
colleagues as a ubiquitously, but differentially expressed protein.73  In this study they speculated 
that the differential expression and the utilization of multiple promoters and transcription factors 
could be the product of varying folate demands in various tissues.73  The expansive expression of 
this protein, along with its ability to act as a “high capacity” carrier of reduced folates has led to 
the belief that RFC is responsible for the bulk influx of reduced folates into mammalian cells, 
thereby having the greatest impact on the intracellular folate pools.69,74  As the major transporter 
of reduced folate derivatives, it is conceivable that both normal and malignant tissues would find 
expression of this protein advantageous for successful DNA replication and for the preservation 
of genomic integrity.  In fact, quantitative real time PCR (RT-PCR) and multiple methods of 
protein detection have validated RFC expression in various human tumors and tissues.  Human 
RFC mRNA transcripts have been identified in cells from various origins including the central 
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nervous, leukocytes, liver, placenta and the intestine.73,75  The presence of RFC expression in 
normal tissues has also implicated the protein as the source of dose-limiting toxicities seen in 
patients treated with antifolates that are accumulated into normal tissues through this mechanism.69 
The bidirectional transport of RFC is driven by the extrusion of organic phosphate which 
allows for the exchangeable influx of reduced folate derivatives and a select number of antifolates 
that are recognized by this protein.25,69  While the exact mechanism of exchange is not fully 
understood, some speculate that it involves a trans-stimulation phenomenon whereby the 
movement of a molecule in one direction enhances or “stimulates” the movement of another 
molecule in the opposite direction.76,77  Optimal transport generally occurs at a neutral pH (7.4), 
although some studies have demonstrated residual RFC transport at a low pH.78,79  Interestingly, 
prior to the discovery of PCFT, RFC was thought to be responsible for low pH folate transport in 
the intestine where the protein is expressed.80  However, more recent experiments have confirmed 
that RFC transport of leucovorin, a reduced folate derivative, was severely impaired at pH 6.5.69,81  
While it has been demonstrated that RFC plays little to no role in the intestinal absorption of dietary 
folates, folate depletion increases the intestinal expression of RFC and the role of RFC in this 
context has yet to be determined.26,55,56  Studies suggest that RFC does not play a major role in the 
tissue absorption and or transport of folic acid (Km~200µM) which may partly explain the reduced 
transport efficiency seen with novel antifolates that closely resemble the chemical structure of folic 
acid.25,75 
The principal route of cellular entry for many “classical” antifolates (i.e., AMT,  
methotrexate (MTX) and pemetrexed (PMX)) is through RFC.  The pharmacological impact of 
RFC expression on the activity of a number of antifolates has been extensively studied.  Many of 
these studies have demonstrated that the functional loss of RFC modulates drug sensitivity.74,82  In 
24 
 
the case where drug influx is completely RFC-dependent, cells exhibit resistance.  Alternatively 
and contrary to what one may expect, the loss of RFC increases drug sensitivity with agents that 
can undergo non-RFC-mediated cell transport, thought to be a consequence of a contracted 
intracellular folate pool, which diminishes competing substrates for targeted enzymes, therefore 
increasing drug potency.82-84 
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Reprinted with permission of  Hou, et al. 85  Copyright (2006) American Society for Biochemistry 
and Molecular Biology. 
 
Figure 1.6: Predicted topology map of human reduced folate carrier (hRFC).  hRFC is an 
integral membrane protein consisting of 12 transmembrane domains and both intracellular and 
extracellular loops.  The diagram attempts to designate specific amino acid sequences within the 
cell membrane, as well as those exposed to the extracellular and cytosolic space.  Topology 
modeling allows for a greater understanding of how hRFC functions and encourages the generation 
of hypotheses surrounding the identification of critical amino acid residues involved in the activity 
of the protein. 
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The Proton-Coupled Folate Transporter (PCFT; SLC46A1) 
The proton couple folate transporter (PCFT) is the most recently identified of the 
predominant mechanisms of folate transport.86  Prior to receiving its current designation as a folate 
uptake mechanism, it was originally named the heme transporter protein-1, which describes its 
ability to effectively transport heme in the intestine (Km:125µM).25,87  The dietary acquisition of 
folates begins in the acidic micro-environment of the duodenum and upper jejunum of the 
intestines.88  The existence of a low pH folate transporter became evident as accumulating data 
ruled out RFC despite its expression in the intestinal brush boarder membrane.  More specifically, 
early experiments using a RFC-null HeLa model validated the existence of a non-RFC low pH 
transport mechanism that was later determined to be PCFT.89  The cloning of PCFT by Qui et al 
formally identified PCFT as the low-pH folate transporter.86  This soon led to structural and 
biological studies to obtain more information about the protein and how it participates in folate 
homeostasis and more importantly what role if any it plays on the pharmacological activity of 
antifolates in clinical use. 
Like RFC, PCFT is an integral membrane protein that participates in the facilitative 
transport of (anti)folates and is also a member of the major facilitator super family (MFS).  
However the transport profile and mechanism of transport is distinct from that of RFC.73  The 
unidirectional transport of folates has been described as electrogenic and proton driven and occurs 
optimally at a low pH (5.5), hence the naming “proton coupled”.73  The charge carried by the 
proton creates an electrochemical gradient which classifies this proton driven mechanism as 
electrogenic.80,90 
The PCFT chromosomal location is 17q11.2 which encodes a 55 kDa protein made up of 
459 amino acids (Figure 1.7).25,91,92  PCFT is encoded from 5 exons with a minimal transcriptional 
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regulatory region located -42 and +96 bases from the transcriptional start site.75,91-93.  Transcription 
of this protein is thought to be governed by a number of factors.  Kruppel like factor -4 (KLF-4), 
hepatocyte nuclear factor (HNF-1) and nuclear respiratory factor -1 (NRF-1) have all been reported 
to enhance PCFT promoter activity resulting in an increase in PCFT transcripts.94,95  Vitamin D 
was also shown to increase PCFT expression via the transactivation of the PCFT promoter by the 
vitamin D receptor (VDR) when heterodimerized with retinoid X receptor –α (RXRα).96  Promoter 
hypermethylation results in decreased transcriptional activity and therefore gene product.93  While 
little is known about the intrinsic transcriptional regulation of PCFT, studies have shown that 
xenobiotics, more specifically, proton pump inhibitors, can decrease intestinal PCFT expression 
in patients administered this type of therapy.97   
Compared to RFC, PCFT has restricted tissue expression that is limited to the duodenum, 
jejunum, liver, kidneys, and choroid plexus and comparably much lower expression in the bone 
marrow and colon.88  A wide range of malignant cells express PCFT, including but not limited to  
tumors of the colon/rectum, lungs, liver and ovaries.98  The expression of PCFT may be especially 
advantageous in tumors with high glycolytic activity or what had been described as “The Warburg 
effect”, creating a proton-rich acidic microenvironment.  In theory, the creation of such a 
microclimate would increase the activity of PCFT and provide a context in which RFC activity is 
reduced.  This very observation is the basis of PCFT-targeted anti-tumor therapy.75  A better 
understanding of the transcriptional regulation of PCFT will undoubtedly result in novel 
approaches and creative strategies to improve drug efficacy in PCFT-expressing tumors. 
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Figure 1.7: Homology model and predicted membrane topology for hPCFT.  (A) The 
cartooned homology model of hPCFT (generated from the bacterial glycerol-6-phosphate 
transporter) demonstrates a side view of the protein.  Featured in this model the two residues (Ala 
335 (red ) and Gly 338 (yellow) that were found to be mutated in human folate malabsorption 
syndrome, which believed to play an important role in protein stability.  In addition, the spatial 
arrangement of transmembrane domains (TMD) 9 and 10 and their proximity to the transport 
channel are also shown.  Much like the predicated membrane topology (B), loops that are believed 
to reside in the intracellular or extracellular space are shown above.  The topology  model  
highlights conserved (black)  and partially conserved residues (arrows) within the TMDS. 
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Folate Receptor alpha (FRα) 
FRs are an extensively studied family of proteins that are recognized for their role in 
embryonic and fetal development where they act as an essential mechanism of folate transport, 
supporting rapid cell division during gestation.  FRs, also known as folate binding proteins (FBP 
or folbp for murine homologs) were first identified in bovine milk in 1972.101,102  Since the 
discovery of these high affinity/low capacity folate binding proteins, four isoforms and pseudo-
genes have been identified.  While each isoform shares some sequence homology (70-80%), they 
each possess distinct structures, patterns of tissue expression (with some overlap), binding affinity 
and stereospecificities.103,104  Collectively, FR’s have the highest affinities toward folic acid, 
physiological reduced folates and formylated THF (5-formylTHF) compared to PCFT and RFC.25  
These features allow FRs to successfully engage in cellular uptake when folate concentrations are 
low.  These genes are all a part of a larger superfamily that includes the riboflavin binding protein 
and the retinbindin, a retinal binding protein.103  Prior to the solving of the crystal structure of FRα, 
homology modeling using bovine riboflavin binding protein was employed to elucidate or to gather 
more insight on the structural characteristics of this protein and possibly other identified isoforms 
due to known similarities of each protein.105   
FR genes, Folr 1-4, are localized to chromosome 11q13.3-14 and are responsible for the 
transcription for FRα, β, γ/γ’ and δ.62,103,104  Of the four isoforms, FRδ is the most recently 
discovered.  While the mouse ortholog, folrbp3, is expressed in the mouse thymus and spleen and 
is thought to play a role in the proliferation of immune cells, expression of this isoform has not 
been detected in human adult or fetal cells.104  The failure to detect FRδ in human tissues has been 
thought to arise from the temporal/spatial regulation and expression of the protein.104  Others 
suggest that like FR pseudogene1 (Folr1p) identified by Raggoussis et al., the delta isoform is a 
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pseudogene in the human genome.104,106  Due to an elusive pattern of expression in human tissues, 
the capacity of this isoform to bind folate is undetermined, as well as its putative role in folate 
metabolism and perhaps cell signaling.   
Much like the delta isoform, little is known about FRγ, when compared to the more 
prominent and widely studied β and α isoforms.  Unlike FRδ, the gamma isoform has been 
identified in human tissue.  The protein was first discovered in 1993 and was identified as an 
overexpressed high affinity folate binding protein in chronic myelogenous leukemia (CML) and 
acute myelogenous leukemia (AML) patient samples.107  Since the discovery of the γ isoform, it 
has been identified in normal hematopoetic cells, bone marrow, spleen and thymus.103  Of the three 
functional forms of FR expressed in human tissues, FRγ is to date, the only identified polymorphic 
isoform of this family.  A genetic polymorphism results in a mutation that codes for a premature 
stop codon leading to the translation of a truncated non-functional protein, FRγ’.108  Despite 
multiple N-glycosylation sites (3) which are shared among all isoforms and are thought to 
contribute to the cell surface expression of the protein,  there is an additional anomaly that 
distinguishes FRγ from its counterparts- this protein is constitutively secreted due to a lack a 
hydrophobic amino acid sequence that serves as a signal for glycosylphosphatidylinositol (GPI) 
modification that anchors the protein to the cell surface.103,109   
FRs are known to exist in membrane bound and soluble states.  Membrane bound receptors 
(α and β) are anchored to the membrane by glycolipids known as GPI anchors.103,110  This GPI 
modification is signaled by the hydrophobic carboxyl terminal segments in the α and β isoforms 
which allow for a post-translational transamidase reaction, resulting in the cleavage of the present 
C-terminus while creating an  amide linkage to the GPI and a newly formed C-terminus.103,110 
Soluble folate binding proteins (sFBP) arise from the membrane-bound forms that undergo well-
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defined cleavage events.  They are generally present in extracellular fluids, which include milk, 
cord blood, urine, and cerebrospinal and amniotic fluids.103  The soluble FR α isoforms are thought 
to be the result of (1.) the phospholipase cleavage of the GPI anchor or (2.) proteolysis by a Mg+2 
dependent protease.103  These mechanisms are thought to be responsible for soluble α isoforms 
detected in KB nasopharyngeal carcinoma cells in culture and those detected from placental cells.  
In contrast, the soluble β isoform is the product of two independent pathways that either result in 
GPI anchor attachment or secretion.103  All soluble forms of the protein have been shown to bind 
and stabilize folates; therefore these soluble proteins may have a functional role in normal 
physiology.103  For instance, the sFBP in milk are thought to play a role in the intestinal absorption 
of folates.103  These soluble proteins may also serve a diagnostic purpose in detecting disease as 
many pathological conditions, including cancer, results in the aberrant shedding of these 
membrane proteins into the circulation where they are not generally detected in healthy 
individuals.103,111   
The FR β has increasingly become the subject of interest due to its role in a number of 
human pathologies, most notably cancer and inflammation.103,112-116  The expression of this 
isoform is confined to hematopoietic cells of the myelomonocytic lineage and the protein is 
routinely used as a differentiation marker in normal hematopoiesis.103  Protein expression extends 
to the placenta and to mature neutrophils with elevated expression seen in activated blood 
monocytes and the expression status remains consistent during their transformation to 
macrophages.103  Macrophages are known to play a critical role in the initiation, maintenance and 
resolution of the inflammatory process.113  Rheumatoid arthritis (RA) is a disease characterized by 
the infiltration of lymphocytes and macrophages to synovial joints, causing proliferation of local 
fibroblasts and severe joint damage.  Activated macrophages in synovial tissues from RA patients 
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were shown to have significant expression of the β isoform.116  The selective expression of FR β 
on this population of macrophages makes this isoform an excellent target for therapies specific to 
this protein isoform.  Presently, the antifolate MTX is the preferred treatment option in patients 
suffering from RA.117  However, MTX substrate promiscuity among other mechanisms of folate 
transport has created a demand for novel therapeutics that have selective uptake by FR β.117-119  
These therapeutics may not only prove useful in the treatment in RA, but they may also show 
efficacy in FR β-expressing malignancies such as leukemia (CML and AML).  Tumor-associated 
macrophages (TAM’s), which also express FRβ, have been implicated in the initiation and 
progression of a number of malignancies.120-122  Folate-based therapies targeted to FR β may 
extend the survival of patients diagnosed with difficult to treat tumors like pancreatic cancer which 
are reported to have significant TAM infiltration.123,124  An additional and perhaps more practical 
application in exploiting the population of TAMs in cancer is the use of fluorescent conjugates 
linked to FR β, which may serve as an optical tool that can aid in detection of relapse (in the case 
of hematopoietic disease), primary tumors and their metastasis.122   
FRα is, by far, the most extensively studied of the four FR isoforms.  While this receptor 
has been well documented as a mechanism of folate transport, additional physiological roles of 
FRα continue to be the subject of many ongoing studies.  Much intrigue surrounds the functional 
role of FRα especially when co-expressed with other high capacity folate uptake mechanisms such 
as PCFT or RFC, which has led to speculation on alternative roles for this receptor.  Undoubtedly, 
FRα has a clear role in the reabsorption of folates from kidney proximal tubules and in embryonic 
development, including the development of the neural tube and transplacental folate transport from 
mother to fetus.  What remains unclear is the utility of this receptor when expressed in other 
epithelial tissues with limited or no access to circulating folates.  One popular line of reasoning 
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suggests that FRα, when expressed in tissues with limited access to circulation, acts as a folate 
scavenger and participates in the transcellular transport of folates, as described in the transport of 
folates across the retinal pigment epithelia, the luminal uterine epithelia during pregnancy and in 
lung epithelia to prevent bacterial growth.125,126  It has been proposed that FRα, like other GPI 
anchored proteins clustered by lipid rafts, participates in signal transduction pathways that are 
involved in regulation, survival and growth.127,128  More studies are required to determine and 
validate the exact signaling pathways that are involved with ligand-bound FRα. 
There are a number of disorders associated with mutations or the functional loss of FRα.  
The homocysteinylation of FRα, a consequence of excess/elevated homocysteine, may lead to the 
development of FRα autoantibodies which are thought to contribute a significant decrease in folate 
uptake, resulting in defects in the developing embryo.129,130  Such deficiencies that arise from 
deleted, dysfunctional or blocked FRα have been linked to NTDs, orofacial cleft, congenital heart 
defects, autism spectrum disorders and cerebral folate deficiency (CFD).130-132  CFD is thought to 
arise from the presence of FRα autoantibodies or a loss of function mutation in the folr1 gene, 
causing a neurological syndrome that presents in children as young as 4 months with cognitive and 
neuromuscular deficits.133,134  Studies have shown that maternal FR autoantibody concentrations 
are linked to NTDs, further highlighting the important role of FRα in embryonic 
development.130,131,135  An incomplete understanding of FRα’s role in signal transduction makes it 
difficult to delineate if folate deficiency or a disruption in signal transduction pathways play a 
causal role in the development of such malformations.  More work in this area may lead to a greater 
understanding of the tissue distribution of this protein and the global importance of its expression, 
in addition its acknowledged role in folate metabolism. 
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As previously mentioned, FRα has a unique and distinct pattern of tissue expression.  In 
adult tissues, FRα is confined to the apical surface (luminal)  of polarized (non-transformed)  cells 
of epithelial origin, including the choroid plexus, proximal renal tubules, fallopian tubes, uterus, 
epididymus, acinar cells of the breast, submandibular salivary and bronchial glands, type 1 and 2 
pnuemocytes in the lung and placental trophoblasts.103  The only known basolateral surface 
expression of this protein has been identified in the epithelia of retinal pigment cells.103  The 
luminal expression of FRα, by virtue of its physical location, makes this receptor inaccessible to 
circulating folates in the blood.136-138  The role that FRα plays in the reabsorption of folates from 
the kidneys creates an opportunity for renal FR to encounter serum folates.103  Interestingly, it has 
been reported that glomerular filtration allows for the separation of low molecular weight FRα-
targeted drugs that are transcytosed, thereby preventing renal accumulation of cytotoxic agents 
and circumventing neurotoxicity.136  
Many epithelial based tumors also express FRα, however, ovarian and endometrial cancers 
are among the most recognized partly due to their consistent and elevated expression of the protein.  
One classic feature of the transformed cell is the absence of cellular organization (loss of polarity) 
and a disruption of cellular architecture.  These structural changes that occur during tumorigenesis 
lead to the altered spatial orientation of the receptor such that it is expressed on the basolateral 
surface.  The newly acquired basolateral surface expression of the receptor on tumors permits the 
sequestration of circulating (anti)folates due to a change in orientation that leads to accessibility.  
We argue that this feature, in addition to the very narrow and restricted tissue expression exhibited 
on normal tissues, makes FRα a rational and attractive target for drug delivery to promote the 
selective killing of FRα-positive tumors.   
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There are many theories surrounding the elevated expression of FRα in select epithelial 
malignancies.  Many of these encouraged thorough investigations of the regulation of folr1 gene 
and gene products in both normal and transformed cells.  The complex regulation of FR genes is 
governed by a variety of factors which include serum folate concentrations, nuclear receptors and 
their respective ligands, and post transcriptional/translational modifications.  Although FR 
isoforms share significant sequence homology, the organization of the gene, the use of alternative 
promoters and alternative splicing distinguishes each isoform from the other while also accounting 
for the differences observed in tissue distribution. 96  
The folr1 gene has a reported length between 6.7 139 and 7.5 kb 140 and is composed of 7 
exons and 6 introns that encodes a 257 residue polypeptide and  a 38-42 kDa protein.141,142  
Multiple transcripts of folr1 have been identified and appear to be the product the use of alternative 
promoters, as well as alternative splicing that occurs at exons1-4.141-143  The promoters responsible 
for the diverse FRα mRNAs are TATA-less and designated P1 and P4, located upstream of exons 
1 and exon 4, respectively (Figure 1.8).103,140  Although they produce divergent transcripts, the 
protein product derived from each promoter is identical.142  The regulation of transcription, the 
efficiency of translation and the length and sequence of the resulting transcripts are where these 
two promoters diverge.82,111,142  Despite these differences, the open reading frame (ORF), 3’ 
untranslated region (UTR) and mRNA stabilities are the same for transcripts derived from both 
promoters in FRα-expressing cells.142  The P1 and P4 promoters are reported to be under tissue-
specific regulation which is thought to account for the abundance of specific transcripts in specific 
tissues. 82,142 
Relative to P4, not much is known  P1 promoter, but this promoter is understood to exhibit 
functional and structural differences from the P4 promoter.141  Transcripts produced by the P1 
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promoter have been identified in the normal human kidney, the testis and the cerebellum of the 
brain.103,141  The multiple initiation sites combined with the alternative splicing of upstream exons 
results in heterogeneity of the 5’ UTR in the transcripts generated and explains the varying lengths 
and sequences of the 5’ UTR among the transcripts.142  The regulation of the P1 promoter in certain 
ovarian cancer cells differs from that which is seen in normal human cells.  Bagnoli and colleagues 
described an inverse relationship between caveolin-1 protein, known to negatively regulate 
intermediates in signal transduction involved with cell proliferation, and FRα expression in human 
ovarian cancer cells.139,144  The result of their efforts determined that caveolin-1 negatively 
regulated FRα expression through repression of the P1 promoter.144  Additional studies examining 
P1 regulation in ovarian carcinomas concluded that the promoter was under the control of a variant 
hepatocyte nuclear protein that enhanced promoter activity via the interaction of a DNA-binding 
site located in the untranslated region of exon1.139  Exon 1 is believed to include the elements 
required for optimal transcriptional activity for the P1-derived FRα transcript in ovarian cancer 
cells.139  For reasons not fully understood, P1 transcripts display a lower rate of translation 
efficiency when compared transcripts generated from the P4 promoter.142  Whether or not 
translation efficiency corresponds to surface expression density, is yet to be determined.  
Additional research is required to validate if similar factors modulate P1 promoter activity in 
normal cells and to determine if there is a direct relationship between promoter activity and overall 
protein expression. 
A number of FRα expressing cells transcribe FRα under the control of the P4 promoter 
including the KB nasopharyngeal carcinoma cells and normal epithelial tissues of the lung, 
placenta, salivary gland, uterus breast and stomach.103  This promoter’s activity is influenced by 
three GC rich sequences that allow for non-canonical SP1 binding, with each of the three sites 
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making a significant contribution to promoter activity.103,143  Multiple sites of potential 
transcription factor binding were reported to be contained within this promoter, including sequence 
motifs for AP2, E-box and the aforementioned SP1 (Figure 1.8).101,140 
mRNA stabilities in FRα-expressing cells have been discussed; irrespective of the 
promoter of origin, all transcripts are reported to have similar stabilities.103,140,142  However a novel 
nuclear post transcriptional mechanism of FRα regulation has been described.  Residing in the 
ORF is a discrete 60 base pair mRNA element that is reported to control the stability of FRα 
mRNA.140  This structure ultimately results in the selective nuclear degradation of FRα transcripts 
in FRα null cells and may be responsible for the  restricted tissue expression seen with this 
protein.140 
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Figure 1.8: Folate receptors gene organization.  Above is a representation of human folate 
receptors α, β and γ gene organization.  Both the β and γ isoforms are thought to be under the 
transcriptional control of a single promoter (indicated here with the letter P) and cis regulatory 
elements Sp1 and ets.  The alpha isoform shows two promoter regions, P1 and P4.  The P4 
promoter includes a Sp1 cis regulatory element.  The length of the exon and intron present are 
featured with numbers above each segment.  An examination of the gene organization includes a 
visual comparing the genomic similarities of each isoform, while offering an explanation in the 
divergence of distribution, expression and function. 
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The inverse relationship between FRα expression levels and serum folate concentrations 
has been well documented.59,145-147  Both in vivo and in vitro models have validated the regulation 
of this isoform by serum and media folate levels, using both folate-deplete and folate-replete 
conditions, the latter including multiple folate metabolites.58,59,148-152  In each instance, restricted 
or reduced folate levels accompanied an increase in FRα expression levels, while increasing folate 
levels reversed the phenotype resulting in reduced expression levels of the protein.  In support of 
these studies, an examination of serum folate levels in patients with FRα-positive tumors 
recapitulated these experimental results, suggesting that this regulation by folate is a naturally 
occurring phenomenon.64,153-156  A consequence of reduced or depleted serum folates is a rise in 
homocysteine levels due to inactivity of MS, which is responsible for the conversion of 
homocysteine to methionine.  Elevated homocysteine levels were shown to encourage or increase 
the interaction between the heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) and the cis-
element in FRα transcripts, which is believed to result in unregulated translation.157  Other studies 
have reported an alteration in the level of mRNA transcripts or amplification of the FR gene.103 
The use of antifolates, more specifically MTX, has also been shown to increase FRα 
expression.81  MTX resistance is thought to be a result of a number of factors including the 
functional loss of RFC or a reduction or silencing of protein expression via gene hypermethylation 
or other mechanisms.25,158,159  Experts suggest that MTX resistant cells experience an increase of 
FRα expression as an attempt to meet the folate requirements of a malignant cell through the use 
of a transport mechanism not affected by drug exposure.81  The exact transcriptional mechanism 
is unknown; however, it has been postulated that DHFR inhibition by MTX may mimic the 
conditions of folate depletion and may trigger the same regulatory pathways that lead to the 
enhancement of FRα expression.81  
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Steroid receptors have also been implicated in the regulation of FRα.  Activation of  
androgen160, glucocorticoid161, and progesterone162 receptors have been associated with increased 
transcriptional activity of the P4 FRα promoter and an increase in cell surface FRα protein 
expression.  Steroid hormone regulation of the FRα P4 promoter by the progesterone and 
glucocorticoid receptors is indirect but it is direct by androgen receptors.  In contrast, the estrogen 
receptor has been identified to negatively regulate FRα through transcriptional repression.163  
Estrogen exerts FRα transcriptional repression by interacting with GC-rich Sp1 binding site(s) of 
the P4 promoter and recruiting the co-repressor SMRT which prevents the cluster of transcriptional 
machinery.163  This finding was thought to help explain the lack of FRα in ER-positive tumors and 
the increased expression in anti-estrogen (tamoxifen) treated tumors. 
Many suspect the physiological role of FRα extends beyond the role it plays in folate 
transport and metabolism.164,165  Studies have shown that cells that are transfected with FRα 
undergo a rapid increase in cellular proliferation and alternatively, cells treated with antibodies, 
sense/antisense particles or oligonucelotides directed to this receptor showed a delay in growth 
and in some cases reversion of the malignant phenotype.127,164-166  Folate metabolism alone cannot 
account for a robust proliferative response but rather alterations in signaling pathways may be 
involved.  Notch and Hes-1 were both implicated in FRα directed cell growth in alpha T3-1 cells 
transfected with FRα.164  In addition to cellular proliferation, FRα has also been linked to cell 
motility, resistance to apoptosis, migration and invasion.167,168  This is somewhat consistent with 
the correlation made between FRα overexpression and a poor prognosis/aggressive phenotype and 
decreased survival in ovarian cancer patients.169,170  FRα expression has been linked to many 
changes seen in malignant transformation which has led some investigators to think the protein 
plays a significant role in normal to malignant transition.168 
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Membrane bound FRs translocate extracellular folates through receptor mediated 
endocytosis.  After endocytosis, the ligand bound receptor is enclosed in an endosome, which 
subsequently acidifies, releasing the ligand from the receptor, after which the free ligand is 
translocated to the cytosol, through some uncharacterized mechanism.  There have been two 
competing theories surrounding the fate of the endocytosed ligand-bound receptor: (1) clathrin-
coated vesicles/pits are involved in intracellular transport; and (2) a clathrin-independent 
mechanism that occurs in lipids rafts which involves the development of early endosomes that 
mature and acidify resulting in the release folates in the intracellular accumulation o.  Many studies 
support the clathrin- independent mechanism as this model appears to be congruent with observed 
absorption, localization and trafficking that has been described for the receptor.110,171,172  FRs are 
proposed to associate with lipid rafts which have been shown to play a role in signal 
transductions;173 this offers some plausibility to the growing hypothesis that FRα is also involved 
in signaling. 128,174 
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Reprinted (adapted) with the permission of Chen et al.175  Copyright (2013) Nature letters. 
Figure 1.9: Ribbon and charge distribution surface model of FRα complex with folic acid 
substrate. (Above) The alpha and beta helices (shown in green) demonstrate how the protein 
interacts with the endogenous ligand, folic acid.  (Top-Right)  A 90 degree rotation of the protein 
offers additional information about the protein-substrate interaction and the key amino acids 
involved in the folic acid recognition/binding process.  (Bottom) The charge distribution surface 
model illustrates folic acid contained within the binding pocket and the charge of the amino acids 
surrounding the binding surface. 
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1.4 Folate based targeted therapy 
Shortly following the discovery and first synthetic synthesis of folic acid, folate analogs 
termed antifolates were the subject of heightened attention resulting from their roles as effective 
agents against hematopoietic malignancies.176,177  More specifically, the development of the first 
clinically used antifolate, AMT, fundamentally changed the treatment of pediatric leukemia and 
ultimately served as a platform for the development of many novel antifolates.176,178,179  The vast 
and rapidly accumulating knowledge of folate metabolism also played an integral role in 
understanding the pharmacology of these analogs in addition to providing direction in the 
development of less toxic congeners.  
Antifolates describe a class of agents that are structural analogs of folate and exert their 
antiproliferative actions through inhibition of enzymes in folate metabolism, resulting in the 
depletion of nucleotides required for DNA replication and DNA repair, and RNA synthesis.180  
Today antifolates remain the most well-studied chemotherapy agents with well-defined and well-
characterized mechanisms of action.  The recent discovery of the molecular structure of FRα and 
growing structural information about the β isoform will encourage the synthesis and development 
of more sophisticated agents with the promise of achieving successful and precise tumor 
targeting.175,181  The identification of malignancies that over-express ideal targetable folate 
transport systems (FR’s and PCFT) are steadily growing.  Recent studies that examined patient 
tumor samples reveal that in vitro tumor models may inaccurately reflect the amount of folate 
transporter proteins that are actually expressed in in vivo patient tumors (personal communication; 
Folate Receptor Conference, Couzumel (2013)).  This overexpression not only increases target 
area and points of entry for FR targeted drugs, but this may also have dramatic impact on tumor 
response and the concentration of drug required for efficacy. 
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There has been tremendous progress in the area of antifolate development since the 
introduction AMT and MTX.  While these agents were the first ground breaking therapies of their 
kind, there are currently a number of novel agents under investigation that target different folate 
pathway enzyme and inhibit growth of neoplastic cells through the disruption of DNA synthesis.  
This diverse array of compounds not only includes new and improved DHFR inhibitors that differ 
from the first generation agents, AMT and MTX, such as pralatrexate, but also PMX which inhibits 
TS.25,182,183  GARFTase inhibitors are under development as well.25  These novel compounds can 
be grouped based on their intended enzyme target, their chemical structure and their ability to 
undergo polyglutamylation. 
GARFTase has become a metabolic target of increasing relevance since the inception of 
lometrexol (LMTX) by the Eli Lilly Corporation in 1985.91,184  Much of the interest surrounding 
LMTX and subsequent GARFTase inhibitors reflects their ability to disable the rate-limiting step 
in the de novo biosynthetic pathway of purines which involves the transfer of the formyl group 
from 10-formyl-THF to the primary amine of β GAR which provides the C8 carbon in the purine 
skeleton.185,186  The disruption of purine production in tumor cells is believed to be a favorable 
feature of a chemotherapeutic drug, as these drugs not only interfere with DNA replication but 
they also disturb the cellular energy balance via ATP depletion, thereby interfering with energy 
requiring processes necessary for cell viability.187  Another interesting and advantageous aspect of 
many of the prototypical GARFTase inhibitors is that they were designed based on the crystal 
structure of either human or E. coli GARFTase, which share homology at the folate co-factor 
binding site.185  The structure-based drug design approach used for these inhibitors may account 
for their characterization as “clean” drugs, in that they have a clear mechanism of action unlike 
nucleoside analogs or purine based drugs that may have some influence on purine synthesis but 
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also possess the capacity to be incorporated into nucleic acids, making their primary function 
indeterminate.185 
LMTX was the first folate-based antipurine that possessed potent inhibitory actions against 
GARFTase.184  Remarkable preclinical data in xenografts of human tumors and murine models of 
solid tumors aided in making LMTX the first GARFTase inhibitor that was clinically 
investigated.184,188  Further development of LMTX was halted during clinical trials due to delayed 
and cumulative side effects, which include severe and unpredictable myelosupression and 
neuropathy that was thought to be a function of a long terminal half-life and liver 
accumulation.91,184,189  RFC-directed transport of LMTX may have been an additional contributing 
factor to toxicity seen in patients.189  Folic acid supplementation was shown to curtail  these 
adverse side effects and allowed patients to tolerate higher concentrations of drug.184  In light of 
this,  new dosing schedules with co-administration of folic acid were implemented in additional 
studies using this drug.190,191  However, further clinical development of LMTX was brought to a 
standstill, reportedly for economic reasons.192 
The LMTX studies validated GARFTase as an important target in de novo purine 
biosynthesis.  In efforts to create novel GARFTase inhibitors that maintained the potent biological 
activity of LMTX, but with reduced untoward toxicities, computer assisted drug design was used 
to create AG2034 and AG2037.  The GRID program, a computer generated method for 
systematically investigating an array of chemical groups and how they interact with suggested 
protein binding sites, revealed two hotspots at the GARFTase binding site that possessed an 
affinity for a thioester probe.185  The structure of human GARFTase was the model for drug 
design.193  The sulfur containing AG2034 was designed to complement the two identified hotspots 
at the GARFTase active site identified by the GRID program.185  AG2034 possessed promising 
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characteristics of an ideal GARFTase inhibitor, with a Ki of 28 nM against the human enzyme,
185 
and the ability to undergo polyglutamylation.185,193  Together, these attributes are thought to be 
responsible for the potent antiproliferative activity seen in L1210 cells (IC50:4 nM) and CCRF-
CEM cells (IC50:2.9 nM).193  Cells with a mutant p53 and/or those lacking a functional G1 
checkpoint were particularly sensitive to purine deprivation elicited by this drug (A549 and MCF-
7).194  After being selected for preclinical trials and tested against a range of murine tumors and 
human xenograft models, AG2034 was taken to clinical trials.  These initial trials were suspended 
to investigate the newer analog AG2037.  AG2037, like AG2034, is a sulfur containing GARFTase 
inhibitor.  However unlike, AG2034 and LMTX, which can achieve cellular entry through both 
RFC and FR, AG2037 is transported by RFC exclusively.185  The selective transport by RFC was 
thought to be ideal at the time.  This was supported by a belief that efficacy of drugs that undergo 
FR-mediated transport would be modified based on the nutritional status (folate intake) of the 
patients.185  A clinical trial with AG2037 in colorectal cancer patients that failed treatment was 
completed in 2004, however this study has no posted or published results to date.  
Attempts to develop improved GARFTase inhibitors continued with the creation of Eli 
Lilly’s GARFT II, also referred to as LY309887.  When compared to LMTX, LY309887 had a 9-
fold greater potency but produced metabolites with reduced polyglutamylation.188  To address the 
issue of polyglutamylation, two monoglutamate GARFTase inhibitors were introduced, 
LY254155 and LY222306.  LY254155 and LY222306 are 2’, 5 thiophene and 2’, 5 furan 
derivatives of LMTX, respectively.  These compounds exhibited greater inhibition against 
GARFTase when compared to the parental compound LMTX and both possessed  reduced affinity 
towards FRα (LY254155: 6 fold, LY222306: 350 fold).195  These agents would presumably be 
valuable in the treatment of tumors with inherently low FPGS activity or tumors that have acquired 
47 
 
resistance to antifolates through reduced expression and or function of FPGS or increased gamma 
glutamyl hydrolase activity.195  The search for an efficacious but well tolerated GARFTase 
inhibitor is ongoing and recent developments in folate transport proteins may produce a generation 
of equally as effective but targeted agents. 
Currently, there is no antifolate that uses AICARFTase as its primary target.  While the 
multi-targeted antifolate, PMX, inhibits AICARFTase as a secondary target, the extent of enzyme 
inhibition by this drug has not been directly quantified.196,197  The rising and alarming acquired 
resistance to current antifolate therapies through multiple mechanisms, including overexpression 
of enzyme targets and decreased expression of essential transport proteins.  The need to circumvent 
antifolate resistance encouraged the design of novel AICARFTase and GARFTase inhibitors 
(among the most infrequently targeted enzymes in folate metabolism) that use an alternative 
mechanism of cellular entry.158 
FR targeted drugs 
Experimental evidence from the Matherly lab and a host of others have shown that classical  
antifolates like MTX, LMTX and PMX bind, at varying degrees, to FRα and elicit a cytotoxic 
effect in FRα-expressing cells, albeit at different concentrations.136,198  Increasing concentrations 
of these agents may introduce off target effects, making it difficult to ascertain if the toxic effects 
were FRα-mediated or otherwise.  Most of the drugs in this class are transported by the 
ubiquitously-expressed RFC, which is thought to lead to intestinal and bone marrow toxicities as 
these are highly proliferative tissues with an increased dependence on the very enzymes these 
drugs inhibit.136   
The adverse effects of these drugs were thought to arise, at least in part, from their RFC 
transport.  This created demand for agents that would reduce undesirable toxicities in normal cells.  
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Ovarian and endometrial cancers were recognized for their expression of FRα and were considered 
difficult to treat with available therapies.  These factors may have led to the quest for FRα-targeted 
therapies.  In the 1980s, efforts to design a FR-based antifolate culminated in the development of 
the TS inhibitor CB3717.199  This agent showed preferential transport by FRα over RFC and could 
be metabolized to polyglutamates, but further development of this compound was halted due to 
nephrotoxicity (thought to be a product of insolubility associated with high dose administration 
rather than FRα transport) and myelosupression.200 
The cyclopenta(g)quinazoline based  drug, CB300638, became the first validated FRα 
targeted TS inhibitor.136  This agent showed high selectivity for FRα when compared to related 
analogs, and showed efficacy in a physiological folate concentration (20 nM) and inhibited TS in 
KB cells but did not compromise normal tissue.201  BCG 945, like CB300638, also a 
cycoplenta(g)quinazoline based compound, showed inhibitory effects against TS in FRα-
expressing cells.202  Due to its in vitro and in vivo efficacy and FRα selectivity, BCG 945 was 
selected as a candidate for phase I clinical trials that are currently on going.202 
De novo purine synthesis has become a rather attractive target in non-RFC based therapies 
with the development of novel GARFTase inhibitors that possess selective membrane transport 
for FRs and PCFT over RFC.  The circumvention of RFC membrane transport by a collection of 
agents within this category can be seen as an improvement upon earlier agents such as LMT which 
was reported to induce severe myelosuppression in clinical trials, likely due to RFC transport.  
Both FR- and PCFT- targeting have distinct advantages that include narrow tissue expression 
(PCFT and FR), optimal performance in tumor acidic microenvironment (PCFT) and basolateral 
expression (circulation accessible) expression only seen in tumor cells (FRα).  These pyrrolo[2,3-
d]pyrimidine compounds are currently undergoing development, but show extraordinary potency 
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toward PCFT- and FRα- positive engineered cell lines, as well as towards PCFT- and FRα-
expressing tumors in both in vivo and in vitro models.198,203-207 
Monoclonal antibodies 
FRα-specific monoclonal antibodies have been developed for both therapeutic and 
diagnostic applications.208  One of the first antibodies directed to FRα was the murine LK26 whose 
further development was impeded by the inability to create a humanized version that maintained 
a suitable affinity towards FRα.208  Farletuzumab (MORab -003), the improved humanized 
“offspring” of LK26, is a composite of murine complementary determining regions into the human 
IG-1 Kappa backbone.125,208,209  This improved congener retained its high affinity to FRα with 
limited reactivity to normal tissue.  Farletuzumab’s proposed mechanism of action is through 
complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity 
(ADCC).125  The antibody is also thought to inhibit cell proliferation through suggested 
interactions with Lyn kinase and membrane signaling complexes that act to inhibit growth.208,209  
The binding of farletuzumab does not interfere with FRα binding to its ligands and was reported 
to marginally reduce the rate of folate delivery, which may offer opportunities for use in 
combination treatment with other FR directed therapies. 
Farletuzumab is reported to be a well-tolerated drug with adverse effects that are well 
managed with antihistamine treatment.208  When used in combination with carboplatin/taxane 
treatment, there was reported clinical activity and improved duration of response when treatment 
was followed with the single agent maintenance with farletuzumab.125  No safety concerns or dose-
limiting toxicities have been reported for farletuzumab and a maximum tolerated dose has not yet 
been  identified.208 
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Folic acid-conjugated therapies 
Folic acid conjugated therapies present a platform to repurpose potent but non- specific 
cytotoxins for delivery in a context that allows for target specificity.  The γ-carboxylic group on 
the folic acid permits linkage of a “warhead” (potent cytotoxin) without disturbing the affinity of 
the ligand to the target.208  Like monocolonal antibodies, folic acid conjugates can be used for 
imaging/diagnostic purposes or therapy, all which is dictated by the conjugate compound.  An 
excellent example of this is seen in vintafolide (EC145) and etarfolatide (EC20) developed by 
Endoycote.  Vintafolide is a folic acid conjugate comprised of a potent vinca alkaloid, 
desaceytlvinblastine hydrazine “warhead”  and etarfolatide is a folic acid conjugate containing the 
medical radioisotope technetinum 99m.210-212  Vintafolide was shown to be most effective (~80% 
overall response rate) in ovarian cancer patients who showed high detection of FRα positive tumors 
by etarfolatide.213  While 90% of ovarian cancers overexpress FRα, there is much variation in the 
level of expression among individuals and subtypes of the disease.  Imaging with etarfolatide will 
aid in the identification of patients who would most benefit from this form of FR-targeted 
treatment.  While these agents performed well in phase I and phase II clinical trials, a phase III 
clinical trial in platinum resistant ovarian cancer was halted due to the failure to produce proper 
efficacy (an improvement in progression free survival).  
Cytotoxic warheads are not limited to the vinca alkaloids.  Promising pre-clinical data were 
obtained from EC0746, a modified folic acid ligand linked to a γ hydrazide analog of AMT.  The 
compound was directed towards FRβ expressing activated macrophages in murine models of 
autoimmune uveitis and encephalomyelitis and showed significant activity through macrophage 
modulation.214  The concept of re-directing RFC-transported cytotoxic antifolates to alternative 
routes for uptake, like FRα, is a very attractive idea.  FRα-mediated uptake by a multi-targeted 
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antifolate, like PMX, may allow ovarian cancer patients to benefit from the activity of this drug 
without the consequence of its debilitating side effects. 
Novel pyrrolo[2,3-d]pyrimidine antifolates 
Pyrrolo[2,3-d]pyrimidines define a collection of heterocyclic compounds that share a 
common heterocyclic fused-ring structure.  These compounds may vary in respect to their 
physiochemical properties as many of them participate in a wide range of biological activities, that 
include functioning as kinase inhibitors215-217, metabolic inhibitors204,205,207,218  and modulators of 
efflux pumps that are often referred to as multi-drug resistance proteins, MRP1s.219  The diverse 
actions of pyrrolo[2,3-d]pyrimidine compounds are thought to be dictated by the addition of 
functional groups (R-group or substituents) at the C4-C7 positions on the molecule218 (Figure 
1.10a).  Studies performed in this body of work as well as earlier studies published by Matherly 
and colleagues203-205,207,220,221 suggest that the chemical and structural properties of the R-groups 
have a tremendous impact on pharmacology of these molecules. 
Pyrrolo[2,3-d]pyrimidines are naturally occurring compounds that can be synthesized by 
variety of organisms including marine and terrestrial bacteria222.  The pyrrolo[2,3-d]pyrimidine 
compounds synthesized by these organisms (also referred to 7-deazapurines) are described as 
secondary metabolites because of their non-essential role in primary metabolism; however these 
compounds are thought to provide an advantage to the organism when present in a host.222  7-
deazapurines are found to be involved in the disruption of cellular process that involve adenine 
nucleosides and nucleotides and were also discovered to perturb cellular metabolism.  These 
compounds are suitable substrates for phosphorylation and can be converted into di-, tri- 
phosphorylated forms which can then be incorporated into DNA and or RNA as modified bases.222  
Together, these features have made these compounds useful tools against bacterial223, fungal and 
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viral infections as well as neoplasms.224,225  Toyocamycin, tubercidine and sangivamycin are all 
soil derived 7-deazapurines which contain the pyrrolopyrimidine scaffold with different 
substituents making the action of each compound distinct from the other (Figure 1.10b).  
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Adpated with permission of McCarty et al. Copyright (2012) Bioorganic Chemistry 
Figure 1.10: Pyrrolo[2,3-d]pyrimidine scaffold molecule.  (A)  The pyrrolo[2,3-d]pyrimidine 
scaffold can be substituted at multiple carbons sites (C4-C7).  The addition of these R-groups have 
been reported to confer selective physiological properties157.  Highly saturated scaffolds 
demonstrate greater biological activity.218  The diversity in function derived from the addition of 
functional groups is beautifully illustrated by toyocamycin, tubercin and sangivamycin (B), a few 
of many naturally occurring 7-deazapurines, which have unique cytotoxic, antibacterial and 
antifungal properties while possessing one distinctive R-group. 
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Pyrrolo[2,3-d]pyrimidine antifolate compounds, like the naturally occurring soil 
metabolites, can be functionally malleable based on the functional group added and the position at 
which the functional group is added.  The lack of crystallographic information for all three forms 
of folate transport proteins necessitated high throughput screening of pyrrolo[2,3-d]pyrimidine 
compounds that showed activity against cell lines engineered to express one of the three transport 
mechanisms.  From such studies, rational drug designs, based on both the biological activity of the 
compounds studied and the known structure of folate metabolism proteins GARFTase and TS, 
created a number of pharmacologically interesting compounds.  The recent determination of the 
FRα crystal structure offers promise to structure-based drug design which will prove invaluable to 
FR-directed therapies and imaging modalities (Figure 1.9). 
Studies performed by the Matherly lab using novel pyrrolo[2,3-d]pyrimidines synthesized 
by Dr. Aleem Gangjee and colleagues at Duquesne University  (Pittsburgh PA), demonstrated 
qualities consistent with that of a classical antifolate, in that membrane transport by RFC, PCFT 
or FR could be identified and their antiproliferative capacities could be linked to the inhibition of 
enzymes involved in folate metabolism.  The position of the substitution on the fused heterocyclic 
ring appears to play an important role in determining the substrate specificity of enzymes in folate 
metabolism, as well as the route of intracellular transport.198,203-207,220,226  Earlier studies performed 
by Gangjee and colleagues suggested that a novel 2-amino-4 oxo-5-substituted pyrrolopyrimidine 
compound possessed  antitumor activity against human head and neck squamous carcinomas and 
CCRF-CEM human leukemic cell lines.227  The antitumor effect was thought to be a function of 
TS suppression, indicated by purified enzyme assays and metabolite protection assays.227  
Alternatively, collaborative studies with the Matherly lab using 6-substituted pyrrolo[2,3-
d]pyrimidines antifolates active against both engineered CHO cell lines  and human tumor cell 
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lines expressing folate transporters, demonstrated inhibition towards GARFTase.  GARFTase 
suppression was demonstrated via metabolic nucleoside protection assays as well as radioactive 
metabolic incorporation assays and isolated enzyme assays.198,205,220  Further, these studies also 
revealed that drug activity can be dictated by the length of the carbon bridge region which connects 
to either a thienoyl or benzoyl ring system.  These studies provided greater insight into the 
structural components required for folate-based targeted drug activity. 
The most potent, tumor-targeted analogs from these studies were lead compounds AG23, 
AG71, and AG94.  These three compounds represent three distinct series of novel pyrrolo[2,3-
d]pyrimidine antifolates.  While structurally unique, each of the lead compounds was found to 
have profound antitumor activity against FRα and PCFT expressing cell lines 
(nanomaolar/subnanomolar range) with minimal or greatly reduced activity towards RFC 
expressing cell lines.198,203-206  These antipurines are effective inhibitors of de novo purine 
synthesis as the studies cited above demonstrated remarkable dose-dependent inhibition of 
GARFTase.  Mindful of the impressive targeted antitumor activity of these leads, congeners of 
these compounds are thoroughly investigated in this body of work to determine how structural 
modifications impact membrane transport, inhibition of targeted enzymes and ultimately cell 
death. 
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Reprinted with the permission of Mitchell-Ryan et al. (2013).  Copyright. J Med Chem. 
 
Figure 1.11: Structure of lead compounds from three distinct series of novel antifolates.  Each 
compound depicted in this figure contains the 2-amino-4-oxo fused hetercyclic ring structure 
(pyrrolo [2,3-d]pyrimidine).  Both AG71 and AG94 conclude their carbon bridge with thienoyl 
ring system unlike AG23 that contains a benzoyl ring in its second ring system.  Each compound 
is substituted at the 6 position.  All novel pyrrolo[2,3-d]pyrimidine compounds presented in this 
work were synthesized by the lab of  collaborating medicinal chemist Dr. Aleem Gangjee. 
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1.5 Ovarian cancer 
Gonadal tissues in the female reproductive tract originate from mesoderm layer of 
embryonic tissue.  A vast majority of the female reproductive tracts is developed from the 
paramesonephric duct, also known as Mullierian ducts, which is responsible for the formation for 
approximately two thirds of the female reproductive tract.228  The ovaries, however, are 
descendants from the genital ridge and are involved in the production of eggs and the hormones 
that help to nurture and prepare eggs for ovulation.229  During ovulation, the eggs travel through 
the Fallopian tube to the uterus where they await fertilization.  There are a host of hormones, 
cytokines and cells that are involved in the cyclical transition of ovulation and menstruation, some 
of which are thought to be influential in ovarian pathogenesis.230-232 
Ovarian cancer is a rare but very lethal gynecological pathology in the United States.  While 
the lifetime risk of developing ovarian cancer is 1.6%, the majority of the women diagnosed will 
ultimately die from the disease, as it is the fifth leading cause of cancer death in American 
women.232,233  The American Cancer Society 2014 statistics estimates that there will 21,980 new 
cases of ovarian which is a negligible decrease from the 2013 estimate of 22,240 cases.233,234  While 
there has been a slight decline in the estimated rate of incidence, the mortality rates remain 
staggering with the 2014 estimate of 14,270, which is a slight increase from the 2013 estimate of 
14,030 deaths.233,234  A vast majority of women diagnosed present at late stage with aggressive 
disease that is often inclined to recur as a fatal treatment resistant disease.  There are a number of 
factors that contribute to late stage (stage III/IV) diagnosis including the lack of appropriate and 
reliable screening modalities and the mismanagement of primary disease.  The mismanagement of 
ovarian cancer, which generally entails the failure to direct patients to experienced gynecological 
oncologists for optimal cytoreduction strategies, has a direct impact on the mortality disparities 
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that exist between populations within this disease.235,236  The molecular profiles of ovarian cancer 
are identical among African-American and Caucasian women, suggesting that there are no genetic 
factors leading to a more aggressive phenotype for African-American women.236,237  However, the 
mortality rates are higher among African-American women, which some believe is a function of 
mismanagement of disease, unequal application of existing treatments and the perceived socio-
economic status of the patient.235,236,238   
Late stage ovarian cancer presents a host of treatment challenges.  An overwhelming 
majority of patients are diagnosed with late-stage ovarian cancer which is no longer confined to 
the ovary.  At this time, treatment options are limited and are generally ineffective with gross 
toxicities to the patients.  Depending on the extent of tumor burden, surgical reduction no longer 
exists as an option.236  An additional determinant in choosing a candidate for debulking surgery is 
the presence of comorbidities that are contraindications for the procedure.239,240  Independent of 
these conundrums, approximately 90% of patients that show initial response to first-line 
platinum/taxane therapy will experience a recurrence of treatment resistant disease.240   
The term ovarian cancer serves an umbrella to describe a collection of malignant tissues 
that are distinguishable by cell type and more recently, by specific molecular events.  These 
subtypes correspond to different types of epithelia and organs within the female reproductive 
system.  Traditionally, ovarian cancers were separated in to three major subtypes based on their 
histology, including: (1) surface epithelium which includes serous, mucinous, endometroid, clear 
cell and Brenner tumors; (2) sex cord-stroma  which includes granulosa cell, sertoli cell , sertoli 
leydig , thecoma, fibroma and steroid tumors; and (3) germ cell tumors that include dysgerminoma, 
yolk sac, embryonal carcinoma, choriocarcinoma and teratomas.241  In line with the initial system 
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of categorizing these tumors, they were further characterized based on clinical behavior as benign, 
malignant and intermediate.242 
Congruent with the general principles of carcinogenesis, ovarian cancer is typically a 
disease of aging with the median age of diagnosis at 63 years.243  Epithelial ovarian cancer (EOC) 
is  the most common form of this disease that accounts for 90% of ovarian cancers.213  Historically 
this subtype of ovarian cancer was thought to arise from ovarian surface epithelium (OSE).244-247  
This early perspective on ovarian cancer suggests that OSE is capable of phenotypic plasticity 
which is derived from the numerous histological transitions that begin with a stromal ovarian 
epithelial inclusion cyst (OEI).247  Through metaplasia, this cyst acquires a Mullerian phenotype 
which eventually evolves into a malignant transformation resulting in the multiple subtypes of 
EOC.247  Critics of this theory express skepticism due to (1) the failure to identify an ovarian 
precursor lesion and (2) there are no reported observations of the transition of an OEI to multiple 
EOC subtypes.247  Further, OSE shows no resemblance to EOC and is distinct from Mullerian 
epithelia.247 However proponents of this theory offer a theory based on experimental models and 
histopathology that suggests that tumor promoting agents have the ability to transform OSE to 
malignant tumors.246 
A growing number of reports suggest that the ovaries serve only as a secondary site and 
that the premalignant lesion is formed at a primary site adjacent to the ovaries.232,247-256  The 
“Secondary Mullerian System Theory” was the first suggestion that ovarian cancer originates from 
an alternate tissue of origin.257  This theory suggest that pelvic tumors with a mullerian phenotype 
(like many ovarian cancers) originate or are derived from mullerian type epithelium (uterus, cervix, 
Fallopian tubes) directly by a metaplastic process.247  This theory fostered the hypothesis that most 
EOC begin as precursor lesion in the distal Fallopian tube. 
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High grade serous carcinoma (HGSC) is the most common and lethal subtype of EOC, 
accounting for 70-80% of the cancers within this category (clear cell carcinoma and endometroid 
carcinoma accounts for 10 %).213,232,247  HGSC frequently displays p53 mutations and genomic 
instability.213,247  This is in stark contrast to type I low grade carcinomas, which include low grade 
serous carcinoma, low grade endometroid carcinoma, clear cell carcinoma, mucinous carcinoma 
and Brenner tumors. 211  Type I tumors are described as a clinically non-aggressive disease that 
generally present at early stage. 209,243  Type I tumors rarely contain p53 mutations and are typified 
by mutations involving KRAS, BRAF, ERBB2, PTEN, CTNNB1, PIK3CA, ARID1A and 
PPP2R1A.213,247  Type I and Type II tumors are distinguishable not only by molecular markers, 
but they differ in presentation, metastatic potential, response to therapy and prognosis.232 
There have been a number of observations that support Fallopian tube involvement in 
ovarian cancer, many of which include the identification of putative precursor lesions.  BRCA1/2 
mutant carriers have a 30-60% increased risk of EOC.232  In one study that examined the Fallopian 
tubes of asymptomatic BRCA1/2 mutation carriers along with women from the general population 
diagnosed with pelvic serous carcinoma, identified at least one of three putative precancerous 
lesions; they include: (1) serous tubal intraepithelial carcinoma (STIC) in the Fallopian tubal 
frimbria; (2) p53 signatures; or (3) frimbrial secretory outgrowth.247  STIC are generally located 
at the distal end of the Fallopian tube and are characterized by frequent p53 mutations, increased 
cell proliferation, DNA damage and a secretory phenotype.252,253,258,259  The multiple shared 
characteristics of STIC to HGSC are believed to be suggestive of a histological relation between 
the two.  Similarities in copy number changes, tubal involvement in HGSC cases, a shared 
secretory phenotype of STIC and HGSC all serve to support the hypothesis that HGSC is the clonal 
outgrowth of STIC lesions.247,260,261  Further, there is a dramatic 98% reduction of ovarian, 
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Fallopian tube and primary peritoneal cancer risk in BRCA1/2 carriers that underwent prophylactic 
bilateral salphingo-oophorectomy which involves the removal of both the ovaries and the 
Fallopian tubes.232  The Sectioning and Extensively Examining the FIMbria protocol (SEE-FIM) 
which was put in place to maximize the detection of precursor lesions in early Fallopian and 
ovarian cancer, demonstrated that women diagnosed with ovarian or primary peritoneal HGSC 
present with STIC (40-60%) that have identical mutational status observed in tumors and also 
show evidence of tubal involvement (70%).232  Altogether, these studies provide a convincing link 
to HGSC and the Fallopian tubes, and point to STIC as the initiating lesion that leads to this 
aggressive cancer.   
The ovaries are believed to be the secondary tumor site for disease that originates in the 
Fallopian tubes.  The proposed mechanism by which this occurs is thought to involve the shedding 
of STIC cells from the distal Fallopian tubes onto the nearby ovaries during ovulation.247  While 
trapped in the ovary, these pre-malignant Fallopian tube-derived cells thrive in the ovulatory 
environment where they are exposed to hormones, pro-inflammatory cytokines and reactive 
oxygen species (ROS) which all may aid in the clonal expansion or re-initiation of cell proliferation 
in the ovary.230,247  This proposed mechanism has helped to construct a new model for the 
development of HGSC which differs from the step-wise development observed in type I low grade 
carcinomas.247 
An additional feature of EOC (including 90% of HGSC) is the overexpression of FRα.  In 
1991, amino acid sequencing analysis determined that the protein enriched on the surface of non-
mucinous ovarian cancer was FRα.213  This identification led to the emergence of the FR protein 
as a tumor marker for this cancer.213  The surface expression of the FRα protein corresponded with 
grade and stage of the tumor.170,262,263  Interestingly, tumors (with some degree of FRα expression) 
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treated with chemotherapy (i.e., MTX, tamoxifen and cisplatin/carboplatin) experienced increased 
(MTX, Tamoxfien) or stable (cisplatin/carboplatin) expression of FRα.264  Knowing this, drugs 
that selectively target FRα can be used as adjuvant therapy in situations where first-line therapies 
have failed. 
Currently, there is no widely accepted comprehensive tumor progression model for ovarian 
cancer, which presents a myriad of challenges in studying this cancer.265  Cell line models (Table 
1.1) and mouse models of ovarian cancer, which are the existing experimental tools, have their 
limitations and in some cases fail to accurately represent the in vivo (patient) tumor.  Molecular 
profiling of ovarian cancers has allowed research to distinguish between high grade (type II) and 
low grade (type I) tumors.266,267  This categorization of tumors based on molecular markers has 
called into question the true histopathology of many of the human ovarian cancer cell lines 
currently used in research.268  Cell line contamination may also be a factor contributing to the 
conflicting reports and misidentification concerning the histopathology of these experimental cell 
lines.269,270  Mouse models of human ovarian cancer make the assumption that the ovary is the 
primary site of disease.  The current models attempt to create tumors in the ovary through the use 
of promoters, many of which are described as leaky.271  Ex vivo implants and use of transgenes 
arguably do not mimic the natural evolution of human EOC and are not representative disease 
models.271  The limitations inherent in both in vivo and in vitro models present an opportunity for 
the development or the investigation of a new model that incorporates an identified and validated 
precursor lesion. 
While there may be continued debate over the etiology of ovarian cancer and the utility of 
the models currently used to study the disease, reproductive, genetic and environmental factors 
continue to be implicated as risk factors in this multifactorial malignancy.  Like most other cancers, 
63 
 
increasing age, inherited genetic cancer syndromes and family history remain important 
determinants of ovarian cancer risk.272 
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Cell line 
Clinical pathology 
Clinical relevance 
 
References 
KB Nasopharyngeal 
carcinoma 
Round et al. 1970,273  
Kou et al. 2003,274   
Jhaveri et al. 2004 
IGROV-1 HGSC (Kulbe, Domcke) 
Serous (Gloss, Dejardins) 
Polymorphous 
adenocarcinoma: 
endometroid,clear cell, 
serous and undifferentiated 
foci (Benard) 
Kulbe et al 2012,275 
Dejarins et al 2014,276 
Gloss et al 2014,277 
Benard et 1985278 
Domcke et al. 2013268 
 
SKOV-3 HGSC Ueda et al 2010,279 
Anglesio et al. 2013,280 
Tsofade et al. 2013,281 
Jiao et al 2011282 
Domcke et al. 2013268 
 
OVCAR-3 HGSC Ueda et al 2010,279 
 
Tsofade et al. 2013,281 
Berger et al. 2001,283 
Domcke et al. 2013268 
Gloss et al 2014277 
CAOV-3 Serous carcinoma 
HGSC (Berger, Domcke)   
Berger et al. 2001,283 
Gloss et al. 2014, 
Domcke et al. 2013268 
TOV-112D  Aggressive stage III 
endometroid tumor 
Gagne et al 2007,284 
 
Table 1.1: A Commonly used FRα positive cell line model with commonly used 
ovarian cell line models.  The table above contains human ovarian cancer cells lines (and one FR 
model, KB) commonly referenced in research literature. 
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Reproductive risk factors 
Ovulation has been thought to contribute to malignant transformation of the epithelium due 
to proliferation that occurs during this process.  This proliferation is believed to promote 
carcinogenesis via the accumulation of genetic mutations in a repetitive “trauma-and-repair” 
cycle.265,272  Therefore, agents that reduce ovulation should have a protective effect against the 
development of disease.285-287  Indeed, oral contraceptive use has been shown to have an inverse 
relationship with ovarian cancer risk in a number of epidemiological studies.285-287  Gestation also 
temporarily suppresses ovulation; therefore parity, number of pregnancies and long term breast 
feeding have all been reported to have protective effects against the development of ovarian 
cancer.265,272,288 
Genetic risk factors 
Women with a family history of ovarian cancer have an increased risk of cancer 
development.  Women with one or more first-degree relatives with ovarian cancer have an 
increased life-time risk of ovarian cancer development of 5-9%.272  Hereditary cancer syndromes, 
like BRCA1/2 mutations, also dramatically increases the risk of developing ovarian cancer; 
however, this only accounts for approximately 5-12% of cases.289  Most ovarian cancer cases arise 
from sporadic mutations that may not be associated with genes found in hereditary breast and 
ovarian cancer (HBOC) and hereditary nonpolyposis colorectal cancer (HNPCC) syndromes.265,272  
Aberrations in TP53, HER2, EGFR, DAB2, AKT, RAS, MYC, PI3K and AR have been suggested 
to play some role in sporadic cases129,130 , yet mechanistic details of their involvement in 
carcinogenesis have not been thoroughly investigated. 
Environmental risk factors 
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Obesity is a common modifier of cancer risk in nearly all types of cancer.  Obesity has 
been linked to inflammation and there is mounting evidence that links both obesity and 
inflammation to cancer risk. 129,130  Pelvic inflammatory disease and endometriosis exposes the 
ovaries and other reproductive organs to prolonged inflammation that may increase ovarian cancer 
risk.290-294   
There have been conflicting reports on the role that genital talcum powder exposure plays 
in the development of ovarian cancer.295  The source surrounding much of this controversy lies in 
the fact that prior to 1976 talc was contaminated with asbestos and much of the data was thought 
to be confounded due to the presence of cancer causing substance.295  However, it has been 
postulated that ovarian cancers can arise from exposure to hydrous magnesium silicates (e.g., 
talcum powder) and recent findings are not tainted by the asbestos association.295,296  Cancerous 
ovaries removed from patients have been shown to contain traces of talc.272   
Early detection and prevention 
To date, there is no reliable screening method to detect early stage ovarian cancers.  
Transvaginal ultrasounds, CA (Cancer Antigen)-125 serum levels and pelvic exams are the 
primary detection/screening tools.129,130,297  Together, these methods are deemed inefficient or 
inadequate due to their inability to capture subtle changes that may occur during tumor initiation 
and early cancer progression in ovarian cancer.297  These modalities also fail to possess the 
specificity and sensitivity required for practical positive predictive values.297  The absence of a 
defined and validated precursor lesion only adds to the challenge in developing a proper screening 
modality.129,130  There are currently efforts to identify new biomarkers to replace or to use in 
conjunction with tools that are currently available.298 
Current treatments for ovarian cancer 
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Ideally, patients who are declared good surgical candidates are recommended for 
cytoreductive surgery followed by adjuvant chemotherapy.129,138,139  Unfortunately, at stages I-II 
of disease, patients with EOC are asymptomatic or symptoms are easily mistaken for innocuous 
conditions.299  This, in conjunction with the lack of adequate early detection screening, results in 
infrequent early stage-diagnosis.129, 297,139  Vaginal bleeding/discharge, frequent urination and 
constipation are typical symptoms of early stage ovarian cancer but are often ignored because they 
are common symptoms of less severe minor gynecological abnormalities.129  Approximately 1.5% 
of patients present with early stage disease for whom complete surgical removal of the tumor can 
be successful and survival is greater than 90% (when cancer is confined to the ovaries); therefore, 
chemotherapy is the primary treatment option for a vast majority of cases.129, 130, 297,300  Over the 
past 40 years, standard therapies used to treat EOC have not significantly extended the median 
overall survival beyond 25-30% in women diagnosed with advanced disease.130,137  Approximately 
75-80% of ovarian cancers exhibit initial chemotherapy sensitivity to first line taxane- and 
platinum-based agents (paclitaxel/docetaxel and cisplatin/carboplatin).  However, most of these 
patients will experience relapse within a year.258,301  Due to the chronic recurring nature of EOC, 
treatment strategies should allow for prolonged treatment by using agents with low toxicity 
profiles, to ensure reasonable patient comfort and minimal disruption to the quality of life for the 
patient. 
There are well recognized cumulative and sometimes irreversible toxicities associated with 
these standard agents (regardless of method of delivery) which makes additional treatment with 
these classes of agents intolerable for patients, thereby reducing the available options in treatment 
and creating a precipitous decline in patients’ quality of life.300-302  Hematological and neurological 
toxicities are of greatest concern as they may impede the patient’s ability to carry out everyday 
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activities.  With this in mind, there is growing support to include “improved quality of life” along 
with “duration of survival” as major considerations in the therapy of advanced cancers.300    
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CHAPTER 2: DISCOVERY OF 5-SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINE 
ANTIFOLATES AS DUAL ACTING INHIBITORS OF GARFTASE AND AICARFTASE 
IN DE NOVO PURINE NUCLEOTIDE BIOSYNTHESIS:  IMPLICATIONS OF 
INHIBITING AICARFTASE TO AMPK ACTIVATION AND ANTI-TUMOR ACTIVITY 
2.1 Introduction 
The antifolates are widely recognized for their inhibition of folate metabolism that leads to 
growth suppression, tumor reduction and remission in a number of malignancies and the reduction 
of inflammation in pro-inflammatory conditions.38,303,304  Major enzyme targets of this particular 
class of agents include TS and DHFR.  Inhibition of these enzymes suppress de novo nucleotide 
biosynthesis, resulting in an imbalance of purine and pyrimidine precursors, rendering cells 
incapable of undergoing accurate DNA replication, ultimately resulting in cell death.  Clinically 
relevant TS and DHFR inhibitors, typified by PMX, and MTX (Figure 2.1) and pralatrexate, 
respectively, continue to play important roles in treating hematologic malignancies and solid 
tumors.25,303 
Antifolates targeting de novo purine nucleotide biosynthesis were also described and 
include LMTX [(6R)5,10-dideazatetrahydrofolate] (Figure 2.1), (2S)-2-[[5-[2-[(6R)-2-amino-4-
oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]thiophene-2-
carbonyl]amino]pentanedioic acid (LY309887)188,305 and (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-
1,6,7,8-tetrahydropyrimido[5,4-bate][1,4]thiazin-6-yl]ethyl]thiophene-2-
carbonyl]amino]pentanedioic acid (AG2034).183  These drugs inhibit the first folate-dependent 
step in purine biosynthesis, catalyzed by GARFTase, and have progressed to clinical trials.69,306,307  
However, their toxicities were dose-limiting, most likely a consequence of their cellular uptake 
and metabolism to polyglutamates in normal tissues.   
The RFC is one of three principal mechanisms of (anti)folate uptake into mammalian 
cells.308  Cellular requirements for folate cofactors for DNA replication provide a plausible 
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explanation for the high levels of RFC in most tumors.  However, demands for folates, and 
consequently RFC, are also shared by normal tissues, such that RFC may not be the optimal 
mechanism for tumor-selective uptake of cytotoxic folate analogs.  Other cellular uptake 
mechanisms, notably the  PCFT and FRs α and β, are also expressed in tumors, while showing 
more restricted expression in normal tissues.92  Furthermore, PCFT is a proton symporter such that 
in the acidic microenvironment generated by glycolytic tumors, membrane transport and selective 
tumor targeting by this mechanism is enhanced.75,88  For FRα, the apical spatial orientation in 
normal epithelial tissues is often disrupted in tumors such that its basolateral membrane expression 
in tumors results in exposure to the circulation.88,92  These features provide compelling rationale 
for developing folate-based therapeutics which target PCFT and FRα for cancer therapy.  
Examples of FRα-targeted therapies include a monoclonal antibody [Farletuzumab 
(Morphotech)]138, a cytotoxic folate conjugate, N-[4-[[(2-amino-1, 4-dihydro-4-oxo-
6pteridinyl)methyl]amino]benzoyl]-L-(-glutamyl-L-α-aspartyl-L-α-aspartyl-L-cysteine [e.g., 
Vintafolide (EC145; Endocyte)],211 and a classical antifolate which is selectively transported into 
cells by FRs over RFC and inhibits de novo thymidylate biosynthesis, [(2R)-2-((4R)-4-carboxy-5-
(4-((2-(hydroxymethyl)-4-oxo-4,6,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)(prop-2-yn-
1-yl)amino)phenyl)-5-oxopentanamido)pentanedioic acid] (ONX0801).202   
PMX is a 5-substituted pyrrolo[2,3-d]pyrimidine antifolate with a 2 carbon bridge linked 
to a p-aminobenzoyl glutamate.  PMX is a good transport substrate for RFC and among the best 
PCFT substrates,69,75,92 yet it is a modest substrate for FRs.198,205-207,220  We previously described 
6-substituted pyrrolo[2,3-d]pyrimidine benzoyl antifolates related to PMX (compounds AG17, 
AG23, AG71 and AG94 (Figure 2.2).198,204  Whereas the 6-regioisomer of PMX was 
pharmacologically inert, the 3- and 4-bridge carbon analogs of this series (compounds AG17 and 
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AG23, respectively) were selectively transported by FRα- and PCFT over RFC and were potently 
inhibitory toward FRα- and PCFT-expressing tumor cells.113,117  Subsequent generation 6-
substituted pyrrolo[2,3-d]pyrimidine thienonyl antifolates (compounds AG71 and AG94) with 3- 
and 4- carbon bridge lengths, respectively, were even more potent as inhibitors of cell proliferation 
then  that of  the  corresponding benzoyl analogs203,207,226.  Compounds AG17, AG23, AG71 and 
AG94 all showed substantial PCFT membrane transport activity but not for RFC.  
PMX was originally described as a “multi-targeted” antifolate with a primary inhibition at 
TS and secondarily at GARFTase and DHFR.309  However, recent studies suggested that although 
TS was the primary cellular target of PMX, AICARFTase could be a pharmacologically important 
target in the presence of excess thymidine (circumvents TS) at sufficiently high PMX 
concentrations.196,197  Hence, in the presence of thymidine, inhibition of proliferation of CCRF-
CEM leukemia cells and solid tumor cell lines was circumvented by hypoxanthine but only 
partially by AICA which is metabolized to ZMP, the AICARFTase substrate.170,171  Further, PMX 
resulted in marked accumulations of ZMP.  By contrast, the 6-substituted pyrrolo[2,3-d]pyrimidine 
analogs AG17, AG23 AG71 and AG94 are inhibitors of GARFTase whose inhibitory effects are 
completely circumvented by AICA.113,117,207,226   
The accumulation of ZMP in PMX-treated cells is intriguing as ZMP is an AMP mimetic 
that activates AMP-activated protein kinase (AMPK).310  AMPK negatively regulates mTOR, a 
critical pro-survival pathway that is activated in many tumor cells along with PI3K/AKT, 
secondary to loss or mutation of PTEN.310-312  This may provide a possible explanation for the 
inhibitory effects of PMX in the presence of thymidine, as purine nucleotides are not 
depleted.170,171  However, this has not been directly tested, as no AICARFTase-targeted drugs 
without TS inhibition have been described. 
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Reprinted with the permission of Mitchell-Ryan et al. (2013) Copyright. J Med Chem 
 
Figure 2.1: Structures of classical antifolates including MTX, PMX, raltitrexed (RTX) and LMTX.  
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Adapted with the permission of Mitchell-Ryan et al. (2013) Copyright. J Med Chem 
 
Figure 2.2: Design of 5-substituted pyrrolo[2,3-d]pyrimidines based on structures of 6-substituted 
analogs 1-4 and pemetrexed.   
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In this chapter, we describe, synthesize and perform a systematical characterization of  the 
in vitro anti-proliferative activities and cellular mechanisms of novel 5-substituted pyrrolo[2,3-
d]pyrimidine antifolates (including PMX) with a benzoyl (AG124-AG129) or thienoyl (AG133-
AG138) rings in the side chain and one-to-six bridge carbons closely related to the 6-substituted 
pyrrolo[2,3-d]pyrimidine analogs AG17, AG23, AG71 and AG94113,117207,226 (Figure 2.2).  We 
reasoned that the 5-substituted analogs might inhibit AICARFTase, analogous to PMX, albeit 
without TS inhibition.  Further, if this was accompanied by FRα and/or PCFT transport selectivity 
over RFC, this would be especially appealing for targeting tumors that express high levels of these 
systems.  
We describe in this chapter the impact of these structural modifications on (i) transporter 
specificity and (ii) the targeted pathway (TS versus de novo purine nucleotide biosynthesis), 
including (iii) the extent of cellular GARFTase and AICARFTase inhibition.  Our results 
document an emerging structure–activity-relationship (SAR) for the pyrrolo[2,3-d]pyrimidine 
antifolates, accompanying translocation of the 6-pyrrolo[2,3-d]pyrimidine substituent to the regio 
5-position, including sustained FRα cellular uptake accompanying restoration of RFC and loss of 
PCFT transport activities.  The 4 carbon bridge analog of the benzoyl series (compound AG127) 
is unique in that it provides the strongest evidence of dual inhibition of both AICARFTase and 
GARFTase exclusive of TS in tumor cells, resulting in depletion of purine nucleotides.  Finally, 
our results directly examine the possibility of whether AMPK activation secondary to 
AICARFTase inhibition contributes to decreased proliferation of KB human tumor cells. 
2.2 Biological evaluation 
Transporter-selectivity for inhibition of cell proliferation by 5- and 6-substituted 
pyrrolo[2,3-d]pyrimidine regioisomers.  Our initial goal was to better define the SARs for 
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membrane transport of pyrrolo[2,3-d]pyrimidine antifolates relating to the impact of 5- versus 6-
substitutions on the pyrrole ring, based on the established antitumor activities of the 6-pyrrolo[2,3-
d]pyrimidine-substituted compounds AG17, AG23, AG71 and AG94 with 3- and 4-bridge 
carbons, respectively, 113,117,156,228 in addition to the preclinical and clinical efficacy of PMX,196  a 
5-substituted pyrrolo[2,3-d]pyrimidine with a 2-carbon bridge (Figure 2.2).  In our previous 
studies,113,117,207,226 compounds AG17, AG23, AG71 and AG94 were efficiently internalized by 
tumor cells via FRα and PCFT but not by RFC, whereas PMX was a substrate by all three 
systems.113,117   
Transporter specificities are exemplified by patterns of inhibition of cell proliferation 
toward isogenic Chinese hamster ovary (CHO) cell models, engineered to express human RFC 
(PC43-10), PCFT (R2/PCFT4), or FRα (RT16),198,205-207,220  treated with compounds AG17, 
AG23, AG71 and AG94 (Table 2.1).  Results are compared to those for RFC-, PCFT-, and FR-
null MTXRIIOuaR2-4 (R2) CHO cells.  As previously reported, 113,117,207,226 compounds AG17, 
AG23, AG71 and AG94 are potent inhibitors of FR-expressing RT16 and D4 cells, and to a 
lesser (albeit still potent) extent, R2/PCFT4 cells.  However, compounds AG17, AG23, AG71 
and AG94 were poorly inhibitory toward RFC-expressing PC43-10 and R2 cells.  Compounds 
AG17, AG23, AG71 and AG94 were also highly active toward KB nasopharengeal carcinoma 
cells and IGROV-1 ovarian carcinoma cells, both of which express elevated FRα, along with 
RFC and PCFT.220  Complete reversal of antiproliferative effects of compounds AG17, AG23, 
AG71 and AG94 toward the FRα-expressing cell lines was seen in the presence of excess (200 
nM) folic acid, further demonstrating that cellular uptake of these analogs are mediated primarily 
via FRα, as previously reported (Table 2.1).198,207  
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5-Substituted pyrrolo[2,3-d]pyrimidine analogs with a side-chain benzoyl group (analogs 
of compounds AG17and AG23) and thienoyl group (analogs of compounds AG71 and AG94) with 
bridge lengths from 1 to 6 carbons (compounds AG124-129 and AG133-138) were synthesized 
and tested for their antiproliferative activities toward the CHO and human tumor models (Table 
2.1).  For the benzoyl series, the 2 carbon 5-pyrrolo[2,3-d]pyrimidine analog (compound AG125) 
is structurally identical to PMX.  5-Substitutions restored RFC-directed anti-proliferative activity, 
as reflected in dramatically increased anti-proliferative effects of this series toward PC43-10 cells 
compared to RFC-, PCFT-, and FR-null R2 cells, in the order (numbers of bridge carbons noted in 
parentheses), AG125 (2C) > AG127 (4C) ~AG126 (3C) > AG128 (5C) >> AG124 (1C) ~AG129 
(6C) (benzoyl series), and AG134 (2C) ~AG136 (4C) > AG135 (3C) > AG137 (5C) >> AG133 
(1C) ~ AG138 (6C) (thiophene series).  Conversely, for PCFT-expressing R2/PCFT4 CHO cells, 
with the exception of compound AG125 and (to a lesser extent) the thiophene analogs AG134 and 
AG137, the antiproliferative effects for the 5-substituted analogs were attenuated compared to the 
6-substituted analogs (e.g., for direct comparisons between paired 5- and 6-substituted analogs, 
compare IC50s for compounds AG17 and AG126 and for compounds AG71 and AG135, 
respectively in Table 1.1).   
With the FRα-expressing sublines, potencies were also reduced for the 5-substituted 
compounds, compared to 6-substituted analogs.  These differences range from slight (compare 
AG23 to AG127, and AG71 to AG28) to substantial (compare AG17 to AG126, AG71 to AG135, 
and AG94 to AG136) (Table 2.1).  In contrast to results for PCFT- and RFC-expressing cells, the 
impacts of bridge lengths were distinctly different between the benzoyl and thienoyl series, with 
anti-proliferative activities toward FRα-expressing RT16 CHO cells in rank order, AG127 (4C) > 
AG125 (2C) > AG128 (5C) > AG126 (3C) > > AG124 (1C) ~ AG129 (6C) (benzoyl series), and 
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AG136 (4C) ~ AG137 (5C) > AG135 (3C) > AG134 (2C) > AG133 (1C) ~ AG138 (6C) (thioenoyl 
series).  An analogous pattern of sensitivities was obtained with KB human tumor cells, and for 
both the KB and RT16 cell lines, inhibitory effects were substantially reversed by 200 nM folic 
acid, confirming FRα as the major uptake mechanism.  While PCFT and RFC likely mediate 
cellular uptake of certain analogs (e.g., AG127 and AG136), uptake by FRα appears to 
predominate. 
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Figure 2.3: Inhibition of RFC-mediated transport and relative FRα-binding affinities by 6- 
(compound 2) and 5- (compound 8) substituted pyrrolo[2,3-d]pyrimidine antifolates.  Panel 
A: To determine if novel antifolates were able to bind human RFC and inhibit transport of 
[3H]MTX, reflecting transport of the novel analogs by RFC, we used PC43-10 CHO cells 
ectopically expressing human RFC but not FRs or PCFT.  Uptake of 0.5 μM [3H]MTX was 
measured at 37˚ C for 2 min in Hepes-buffered saline (pH 7.2), in the absence or presence of 10 
µM of non-radioactive inhibitors, including compound (Cpd) AG23, AG71, AG127 or AG136, or 
the classical agents, PMX and MTX.  Experimental details are described in the Methods and 
Materials.  Internalized [3H]MTX was normalized to total cell protein and expressed as pmol/mg 
protein.  Transport results are compared to those for RFC-null R2 cells.  Panel B: To assess the 
relative binding affinities of the novel antifolates to FRα, we performed direct competitive binding 
assays using [3H]folic acid (FA) in the FRα-engineered CHO cell line, RT16.  RT16 cells were 
washed, then incubated with Hank’s balanced salts solution containing 50 nM [3H]folic acid in the 
absence or presence of unlabeled 6-pyrrolo[2,3-d]pyrimidine compounds AG23, AG71, AG127or 
AG136, or folic acid, PMX, or MTX at various concentrations.  Relative binding affinities were 
calculated as the inverse molar ratios of unlabeled ligands required to inhibit [3H]folic acid binding 
by 50%.  By definition, the relative affinity of folic acid for FRα is 1.  Further, details for the 
transport and binding assays are provided in the Methods and Materials.  For both series of 
experiments, results are presented as mean values plus/minus standard errors from 3 experiments. 
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To complement results showing anti-proliferative effects of the most potent 5-substituted 
analogs, AG127 and AG136, toward PC43-10 CHO cells expressing human RFC, we measured 
competitive inhibitions of [3H]MTX (0.5 µM) transport in this model over 2 minutes at 37° C 
(Figure 2.3A).  MTX is a well-characterized surrogate substrate for RFC and the extent of 
[3H]MTX transport inhibition by competitive unlabeled (anti)folate ligands correlates with their 
membrane transport by RFC.9  For our study, we compared inhibitory effects of 10 μM of 
compound AG127 and AG136, to those for the corresponding 6-substituted compound AG23 and 
AG71, and to PMX and MTX.  Transporter-null R2 cells were used to as a measure of baseline 
[3H]MTX uptake.  Whereas AG23 and AG71 were poor inhibitors of [3H]MTX uptake (< 25% 
inhibition), compound AG127 and AG136 were a reasonably good inhibitors (>90%), with a 
inhibitory potency approximating that for PMX and net transport only slightly greater than the 
very low levels recorded for R2 cells.  Clearly, unlike the 6-substituted pyrrolo[2,3-d]pyrimidine 
analogs, the 5-substituted compounds lack specificity for FRα and/or PCFT over RFC.   
Compounds AG127 and AG136 showed anti-proliferative effects toward FRα-expressing 
RT16 CHO cells and KB human tumor cells (Table 2.1).  To directly demonstrate drug binding to 
FRα, a prerequisite of cellular uptake by this endocytotic mechanism, we used competitive binding 
assays with [3H]folic acid with RT16 cells, treated with unlabeled ligands which compete for FRα 
binding16-20 (Figure 2.3B).  Relative FRα binding affinities for the 5- (compounds AG127 and 
AG136) versus 6-substituted (compounds AG23 and AG71) analogs paralleled their anti-
proliferative activities.  However, this correlation did not quite extend to PMX (compound AG125) 
or to MTX, indicating that multiple factors in addition to FRα binding affinities contribute to net 
growth inhibition of FRα-expressing cells for these antifolates.  
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A. 
Compound Structure 
hRFC hFRα hPCFT 
PC43-10 R2 RT16 RT16 (+FA) R2/hPCFT4 R2(VC) 
1-AG17 6-pyr/3C/Benzoyl 648.6(38.1) >1000 4.1(1.6) >1000 23.0(3.3) >1000 
2-AG23 6-pyr/4C/Benzoyl >1000 >1000 6.3 (1.6) >1000 213 (28) >1000 
3-AG71 6-pyr/3C/Thieno >1000 >1000 1.82(0.28) >1000 43.4(4.1) >1000 
4-AG94 6-pyr/4C/Thieno 101.0(16.6) 273.5(49.1) 0.31(0.14) >1000 3.34(0.26) 288(12) 
5-AG124 5-pyr/1C/Benzoyl >1000 >1000 >1000 >1000 >1000 >1000 
6-AG125 5-pyr/2C/Benzoyl 30.6 (6.2) >1000 18.2(3.8) >1000 22.3(8.6) >1000 
7-AG126 5-pyr/3C/Benzoyl 68.8(21.2) >1000 72.0(27.1) >1000 329(61) >1000 
8-AG127 5-pyr/4C/Benzoyl 56.6(5.8) >1000 8.6(2.1) >1000 840(90) >1000 
9-AG128 5-pyr/5C/Benzoyl 196.4 (55.0) >1000 33.5(2.5) >1000 >1000 >1000 
10-AG129 5-pyr/6C/Benzoyl >1000 >1000 >1000 >1000 >1000 >1000 
11-AG133 5-pyr/1C/Thieno >1000 >1000 >1000 >1000 468 (112) >1000 
12-AG134 5-pyr/2C/Thieno 59.8(11.1) >1000 550 (50) >1000 80.2(5.5) >1000 
13-AG135 5-pyr/3C/Thieno 116.0(22.5) >1000 109 (44) >1000 312 (90) >1000 
14-AG136 5-pyr/4C/Thieno 38.3(6.6) >1000 49.3(11.5) >1000 141(40) >1000 
15-AG137 5-pyr/5C/Thieno 243.2(49.9) >1000 45.5(22.8) >1000 57.4(21.4) >1000 
16-AG138 5-pyr/6C/Thieno >1000 >1000 >1000 >1000 >1000 >1000 
MTX - 12(1.1) 216(8.7) 114(31) 461(62) 120.5(16.8) >1000 
RTX - 6.3(1.3) >1000 15(5) >1000 99.5(11.4) >1000 
LMTX - 12(2.3) >1000 12(8) 188(41) 38.0(5.3) >1000 
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B. 
Compound Structure 
hRFC/ FRα/hPCFT 
KB KB (+FA) 
KB (+Thd/Ade/ 
AICA) 
IGROV-1 IGROV-1 
(+FA) 
1-AG17 6-pyr/3C/Benzoyl 1.7(0.4) >1000 Ade/AICA -- -- 
2-AG23 6-pyr/4C/Benzoyl 1.9 (0.7) >1000 Ade/AICA 3.9 (.98) >1000 
3-AG71 6-pyr/3C/Thieno 0.026(0.03) >1000 Ade/AICA .98 (2.0) >1000 
4-AG94 6-pyr/4C/Thieno 0.55(0.10) >1000 Ade/AICA -- -- 
5-AG124 5-pyr/1C/Benzoyl >1000 >1000 -- -- -- 
6-AG125 5-pyr/2C/Benzoyl 9.94(3.11) 690 (310) Thd/Ade 60.7 (7.1) >1000 
7-AG126 5-pyr/3C/Benzoyl 49.5(13.2) 533(233) Ade 100 (55) >1000 
8-AG127 5-pyr/4C/Benzoyl 12.7(5.4) 700 (300) Ade 94.3 (7.6) >1000 
9-AG128 5-pyr/5C/Benzoyl 17.3(8.9) 898(102) Ade/AICA -- -- 
10-AG129 5-pyr/6C/Benzoyl >1000 >1000 -- -- -- 
11-AG133 5-pyr/1C/Thieno >1000 >1000 -- -- -- 
12-AG134 5-pyr/2C/Thieno 875 (125) >1000 -- -- -- 
13-AG135 5-pyr/3C/Thieno 211 (58) 825(175) Ade/AICA -- -- 
14-AG136 5-pyr/4C/Thieno 66.0(14.4) 900 (100) Ade/AICA 29.5 (14.9) >1000 
15-AG137 5-pyr/5C/Thieno 41.7(10.1) >1000 Ade -- -- 
16-AG138 5-pyr/6C/Thieno >1000 >1000 - -- -- 
MTX - 6.0(0.6) 20(2.4) -- -- -- 
RTX - 5.9(2.2) 22(5) -- -- -- 
LMTX - 1.2(0.6) 31(7) -- -- -- 
Table 2.1: IC50s (in nM) for 5- and 6-substituted pyrrrolo[2,3-d]pyrimidine antifolates and 
classical antifolates in RFC-, PCFT-, and FR-expressing cell lines.  Growth inhibition assays 
were performed for CHO sublines engineered to express human RFC (PC43-10), FRα (RT16), or 
PCFT (R2/PCFT4), for comparison with transporter-null [R2, R2(VC)] CHO cells (A), and for the 
KB  human tumor subline (express RFC, FRα, and PCFT) (B), as described in the Methods and 
Materials.  For the FRα experiments, growth inhibition assays were performed in the presence and 
the absence of 200 nM folic acid (FA).  The data shown are mean values from 3-10 experiments 
(plus/minus SEM in parentheses).  Results are presented as IC50 values, corresponding to the 
concentrations that inhibit growth by 50% relative to cells incubated without drug.  Data for MTX, 
RTX, LMTX, and compounds AG17, AG23, AG71, and AG94 (Figure 2.1) were previously 
published (structures of these compounds are in Figure 1 whereas the structures for compounds 
AG133-AG138 are shown in Figure 2.2.  For KB cells, data are shown for the protective effects 
of nucleoside additions including adenosine (60 µM), thymidine (10 µM), or AICA (320 µM).  
Examples of these data are graphed in Figure 2.4.  For the 5- and 6-pyrrolo-2,3-d)pyrimidine 
compounds AG17-AG138, the structural motifs are documented, i.e., the pyrrole 
substitution/bridge length/B-ring structure.  The most potent compounds in the 5-substituted series 
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(AG127 and AG136), along with their 6- substituted analogs (AG23 and AG71) and PMX 
(AG125) were evaluated for anti-tumor activity in the human ovarian cancer cell line IGROV-1.  
Undefined abbreviations: Cpd, compound; ND, not determined.  The results with compounds 
AG17, AG23, AG71 and AG94 were previously reported.198,204,207,226  
84 
 
Inhibition of de novo purine nucleotide biosynthesis by both 5- and 6-pyrrolo[2,3-
d]pyrimidine compounds leads to a cytotoxic response via purine nucleotide depletion.  De 
novo purine nucleotide biosynthesis includes 10 reactions by which phosphoribosyl pyrophosphate 
(PRPP) is converted into inosine monophosphate (IMP), the precursor of AMP and GMP (refer to 
Figure 1.3 in chapter 1).  There are two folate-dependent enzymes in the pathway which are 
possible targets for folate-based therapies i.e., GARFTase (catalyzes steps 2, 3 and 5) and 
AICARFTase (catalyzes steps 9 and 10).  Previous studies established that GARFTase was the 
intracellular enzyme target for LMTX183,313 and for compounds AG17, AG23, AG71 and 
AG94.198,207  For PMX, TS is the primary intracellular target, although modest inhibitions of 
GARFTase and DHFR were also reported.309  Most recently, AICARFTase was implicated as a 
potentially important secondary enzyme target for PMX (in the presence of excess thymidine to 
circumvent TS inhibition) by nucleoside protection experiments and metabolic assays.196,197  
To identify the targeted pathway for 6-substituted compounds AG23 and AG71, we 
previously used nucleoside protection experiments with adenosine (60 µM) and thymidine (10 
µM), to distinguish de novo purine nucleotide from thymidylate biosynthesis, respectively.198,204-
207,220,313  To further identify the likely folate metabolizing enzyme targets in purine nucleotide 
biosynthesis (GARFTase versus AICARFTase), cells were treated with the antifolates in the 
presence of AICA (320 µM), which is metabolized to AICA ribonucleotide (ZMP), the substrate 
for AICARFTase substrate, thus bypassing the step catalyzed by GARFTase198,204-207,220,313  
(Figure 1.3).   
We used this approach for KB cells treated with compounds AG125-128 and AG135-
AG137, with results compared to those for compounds AG23 and AG71, and to PMX (compound 
AG125) (Table 2.1; Figure 2.4 shows the nucleoside protection results for PMX and compounds 
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AG23 and AG71 compared to those for compounds AG127 and AG136).  With compounds AG23 
and AG71, both adenosine and AICA were completely protective, establishing de novo purine 
biosynthesis and GARFTase as the principal targets.198,204,207  With PMX, thymidine, adenosine, 
and AICA were all partially protective, albeit to different extents.  Combined thymidine and 
adenosine completely protected KB cells from the growth inhibitory effects of PMX (not shown).  
The growth inhibitory effects of the 5-substituted compounds AG126-AG128, AG135 and 137 
with KB cells were unaffected by excess thymidine but were completely reversed in the presence 
of adenosine alone, indicating that exclusively de novo purine nucleotide synthesis was being 
targeted (rather than combined thymidylate and purine nucleotide synthesis).  Whereas AICA 
alone completely protected KB cells from the inhibitory effects of compound AG128 andAG135, 
AICA alone was only partially protective with compounds AG126, AG127 and AG137.    
Thus, inhibition of purine nucleotide biosynthesis by compounds AG126, AG127 and 
AG136 is likely a composite effect of dual inhibitions involving both GARFTase and 
AICARFTase.  These results strongly imply that shifting the substituent from the 6- to the 5-
position on the pyrrolo[2,3-d]pyrimidine ring system results in an altered inhibition of the targeted 
enzymes. 
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Figure 2.4: Cell proliferation assays with protection by nucleosides including thymidine and 
adenosine and 5-amino-imidazole-4-carboxamide (AICA) to identify intracellular targets of 
compounds AG127 and AG136.  To identify the targeted pathways and the folate-dependent 
intracellular enzymes in KB cells treated with compounds AG127 and AG136 (1-1000 nM), cell 
proliferation assays were performed in the presence of 10 μM thymidine, 60 μM adenosine or 320 
μM AICA.  Relative cell numbers were measured with a fluorescence-based viability assays 
(CellTiterBlue™).  Results were normalized to those for untreated cells (no drug) and for 
compounds AG127 and AG136, results are shown in comparison to those for PMX and compound 
AG71.  Details are provided in the Methods and Materials.  Results shown are representative of 
triplicate experiments.  Analogous experiments were performed for compounds AG126 and 
AG128 and the results are summarized in Table 2.1. 
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Decreased purine nucleotide biosynthesis resulting from inhibition of folate-dependent 
enzymes can be monitored by following changes in ATP pools, a surrogate measure of total purine 
nucleotides (Figure 2.5).  KB tumor cells were treated for 24 h with the novel 5-substituted analog 
AG127 and AG136, or the corresponding 6-subsituted regioisomers, compounds AG23 and AG71, 
respectively.  A parallel incubation was performed with PMX.  ATP pools were extracted and 
measured by an HPLC ion-pairing method.204,314  In KB cells, following a 24 h incubation, 
compounds AG127 and AG136, like AG23 and AG71, potently depleted ATP pools (>90%), 
whereas PMX was much less effective (~60% inhibition). 
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Figure 2.5: Compounds AG23, AG71 AG127and AG136 deplete ATP pools in KB cells.  KB cells were 
treated with 1 µM of the novel 5- and 6-substituted pyrrolo[2,3-d]pyrimidine antifolates AG23, AG71 
AG127 and AG136 , or with PMX for 24 h.  Nucleotides were extracted and analyzed by ion-pair HPLC 
using a C18 column.  Experimental details are in the Methods and Materials.  Results are presented as mean 
values +/- standard errors. 
  
89 
 
Inhibition of de novo purine biosynthesis by compound 8 results in cytotoxicity and 
apoptosis.  To confirm that depletion of purine nucleotides by the most potent 5-substituted 
analog, compound AG127, results in cytotoxicity toward KB cells, we performed colony-forming 
assays.  In these experiments, KB tumor cells were treated with various concentrations (1-10 µM) 
for 48 h, then washed and plated without drug.  Colonies were enumerated after 10 days (Figure 
2.6A).  Following drug exposures, inhibitory effects of compound AG127 were irreversible with 
complete loss of colony formation at the highest drug concentrations, thereby establishing 
compound AG127 as cytotoxic.  
Programmed cell death type I (mitochondrial pathway) requires ATP to form the death 
complex with cytochrome C and caspase 9 and to carry out other energy-requiring processes for 
enzymatic degradation and modification of cellular components.315  Previous studies suggested 
that the 6-substituted pyrrolo[2,3-d]pyrimidine antipurine antifolate AG17 was capable of 
inducing apoptosis, albeit less than that indicated by daunorubicin over 24 h.198  Additional 
experiments were performed with KB cells treated with compound AG127 to assess its effects on 
cell cycle progression and induction of apoptosis, with comparisons to PMX and compound AG23.  
Cells were exposed to 1 µM drugs for 48 or 96 h.  Cultures were then divided, with one fraction 
fixed and stained with propidium iodide (PI) for flow cytometry analysis of cell cycle distribution 
(Figure 2.6B).  An additional fraction was assayed for apoptosis by flow cytometry with annexin 
V/fluorescein isothiocyanate (FITC) /7-amino actinomycin D (AAD) staining (Figure 2.6C).   
At 48 h, minimal effects on the cell cycle were observed, except for PMX, which induced 
a G1/Go-phase arrest relative to the untreated (DMSO) control (data not shown).  At 96 h, all 
compounds tested increased the percentages of cells in S-phase (albeit to different extents), while 
reducing those in the G1/Go- and G2/M-phases of the cell cycle.  The histograms display a change 
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in DNA content in cells treated with AG23 and AG127, suggesting aneuploidy. A prominent 
increase in the sub-G1 population at 96 h was also seen (Figure 2.6B; most notable for compounds 
AG23 and AG127), indicating apoptosis was induced.    
Annexin V-FITC staining was used to further monitor induction of apoptosis.  For 
compounds AG23 and AG127, as well as PMX, positive annexin V-FITC staining increased over 
time (results for 96 h are shown in Figure 2.6C, with distinct increases in both early (annexin-V-
FITChigh/7-AADlow) and late apoptotic fractions (annexin-V-FITChigh/7-AADhigh), compared to 
those for the untreated (DMSO) control (i.e., the fractions of cells in early apoptosis were 33.8% 
and 0.49% for compound AG127-treated and control cells, respectively, whereas the fractions in 
late apoptosis at 96 h were 26.7% and 2.1%, respectively).  Nearly identical results were obtained 
with compound AG71, although for PMX, the distribution between the early and late apoptotic 
fractions was somewhat different.  Thus, the 5- and 6-substituted pyrrolo[2,3-d]pyrimidines AG23 
and AG127 can induce apoptosis, resulting in cell death in spite of depleted ATP pools. 
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Figure 2.6: Inhibition of de novo purine biosynthesis by compound AG127 results in 
cytotoxicity and apoptosis.  Panel A. KB cells (1000 cells) were treated with compound AG127 
(0.5 to 10 µM) for 48 h, after which cells were washed (3x) and complete drug-free medium was 
added.  Colonies were allowed to grow for 10 days, at which time they were stained with methylene 
blue and counted.  Results are presented as mean values +/- standard errors from 3 experiments.  
Panel B:  Cell cycle analysis.  KB cells were treated with 1 µM antifolates (PMX, compound 
AG23, compound AG127) for 96 h, washed, then fixed and stained with PI. Cell cycle 
distributions were analyzed by flow cytometry.  The sub-G1 fraction (white fill) increased from 
3.52% in the absence of drugs upon treatment with PMX (17.3%) or compounds AG23 (45.1%) 
or AG127 (36.7%).  For the non-sub-G1 population, the cell cycle distributions [colors are green 
for G1/G0, yellow for S, and blue for G2/M] are as follows: no additions, 67.4% G1/G0, 15.9% S, 
13.2% G2/M; PMX, 47.8% G1/G0, 27.5% S, 7.46% G2/M; compound AG23, 22.3% G1/G0, 31.4% 
S, 1.18% G2/M; and compound AG127, 12.9% G1/G0, 48.2% S, 2.31% G2/M.  Panel C:  Analysis 
of apoptosis by annexin V-FITC/7-AAD staining and flow cytometry are shown for KB cells 
treated with PMX, or with compounds AG23 or AG127 for 96 h.  Results are compared to those 
for controls treated with DMSO in lieu of drug.  The percentages of cells in each quadrant [viable 
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cells (annexin V-FITClow/7-AADlow;Q4), early apoptosis (annexin V-FITChigh/7-AADlow;Q3), and 
late apoptosis/necrosis (annexin V-FITChigh/7-AADhigh;Q2) are summarized.  These experiments 
were ran with the assistance of Dr Eric Hales who performed the data analysis. 
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Dual Inhibition of GARFTase and AICARFTase by 5-substituted pyrrolo[2,3-
d]pyrimidine antifolates and downstream effects of accumulated ZMP on AMPK as 
mechanisms resulting in cytotoxicity.  Experiments were performed to measure cellular 
GARFTase activity in KB tumor cells treated with the 6- (compounds AG23 and AG71) and 5-
substituted (compounds AG127 and AG136, and PMX) pyrrolo[2,3-d]pyrimidines.  For this 
purpose, we used an in situ activity assay for GARFTase which measures incorporation of  
[14C]glycine into [14C]formyl GAR in the presence of azaserine over 16 h.147,153-156,168,233 
Cells were harvested, washed with PBS and treated with trichloroacetic acid (TCA).  Following 
deproteinization, acid-soluble metabolites were ether-extracted and fractionated by ion-exchange 
chromatography, permitting isolation and quantitation of [14C]formyl GAR.  Both 5- and 6-
substituted analogs exhibited a dose-dependent decrease in [14C]formyl GAR.  Compound AG71 
was the most potent of the analogs tested in contrast to its 5-substituted analog, compound AG136, 
which was the least.  However, compound AG23 was more potent than either PMX or compound 
AG127, with an IC50 for this compound exceeding those for 5-substituted compounds by 2- to 5-
fold (Figure 2.7). 
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Figure 2.7: In situ GARFT assay.  GARFT activity and inhibition by 5- and 6-substituted 
pyrrolo[2,3-d]pyrimidine analogs, AG23, AG71, AG127, AG136 and PMX were evaluated in situ 
with KB cells.  KB cells were treated with drugs in the presence of 4 µM azaserine.  [14C]glycine 
and L-glutamine were added and cells were incubated for 16 h at 37oC.  Radioactive metabolites 
were extracted and fractionated on 1 cm columns of AG1 x 8 (Cl-); the fractions were collected 
and determined for radioactivity.  Accumulation of [14C]formyl GAR was calculated as a percent 
of vehicle control over a range of antifolate concentrations.  Results are presented as mean values 
± standard errors from 3 experiments.  IC50s are summarized in the table.  Details are described in 
the Methods and Materials. 
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The anti-proliferative effects of PMX independent of its impact on TS were previously 
attributed to its inhibition of AICARFTase in addition to GARFTase, as reflected in incomplete 
protection by AICA in the presence of thymidine, and the accumulation of the AICARFTase 
substrate ZMP in tumor cell lines treated with PMX, as measured by anion-exchange HPLC 
analysis.196,197  ZMP accumulation showed both dose- and time-dependence for PMX and resulted 
in activation of AMPK via its role as an AMP mimetic and suppression of mTOR.   
To validate the findings from our AICA protection experiments with lead 5-substituted 
analog, compound AG127 (Figure 2.4), and to explore whether AICARFTase is a bona fide target 
for the novel 5-substituted pyrrolo[2,3-d]pyrimidine AG127, analogous experiments were 
performed to measure accumulation of ZMP in KB cells treated with 1 µM of compound AG127 
or PMX, as a measure of AICARFTase inhibition.  ZMP accumulated in a linear fashion for up to 
48 h in KB tumor cells for both compounds (not shown), with PMX showing approximately 2-
fold increased levels over compound AG127 (Figure 2.8A).   
To verify the impact of ZMP accumulation on AMPK phosphorylation in KB cells treated 
with compound AG127 or with PMX, western blot analysis was performed of total and 
phosphorylated AMPK in KB cells treated with these antifolates for 48 h, compared to levels of 
phospho-AMPK resulting from treatment with established AMPK activators including AICA, 
AICA ribonucleoside, and metformin316  (Figure 2.8B).  Although KB cells are LKB1-null (the 
principal upstream kinase responsible for phosphorylating AMPK), AMPK is still activated upon 
treatment with known AMPK activators.  While AMPK is activated by PMX, compound AG127 
was not significantly activating despite the accumulation of ZMP.  Interestingly, neither AICA 
(not shown) nor metformin (data not shown) at concentrations found to activate AMPK were 
growth inhibitory toward KB cells.  
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Figure 2.8: Accumulation of ZMP by 5-substituted pyrrolo[2,3-d]pyrimidines PMX, and 
compound AG127.  Panel A: ZMP (AICA ribonucleotide) accumulation was measured in KB 
cells treated for 48 h with the 5-substituted pyrrolo[2,3-d]pyrimidine antifolate AG127, or PMX.  
Methods for extracting nucleotide metabolites and for measuring ZMP levels by ion-exchange 
HPLC are detailed in the Methods and Materials.  Panel B: KB cells were treated at indicated for 
48 h, followed by western analysis of phosphorylated AMPK on a 4-20% gradient gel.  Blots were 
probed with antibodies to phospho- and total AMPK, and to β-actin. 
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2.3 Discussion 
The development of rationally designed cytotoxic antifolates remains an area of significant 
interest to anticancer drug development, as exemplified by the relatively recent approval of 
PMX317 and pralatrexate318 for cancer, more than 50 years since introduction of MTX.319  
Unfortunately, the ubiquitous presence of RFC may contribute to unwanted toxicities of these 
classical antifolates toward normal tissues.  Based on this, growing attention has focused on 
developing novel folate-based compounds with tumor targeting premised on transport selectivity 
for FRs or PCFT over RFC,75,198,204-207,220 a pursuit that until recently175 continued to be challenged 
by the lack of structural information on the major folate transport systems.  
The antitumor efficacy for the 5-substituted 2-carbon bridge pyrrolo[2,3-d]pyrimidine 
PMX reflects its cellular uptake by all the major folate transport systems.147,153-156  While the 
corresponding 6-substituted analog of PMX was pharmacologically inert, with increasing bridge 
lengths, 6-substituted pyrrolo[2,3-d]pyrimidines were surprisingly potent inhibitors of cell 
proliferation, although membrane transport by RFC was lost.204,320  The 6-pyrrolo[2,3-
d]pyrimidine benzoyl analogs with 3 and  4 bridge carbons, compounds AG17 and AG23, 
respectively, were the most active of this series, reflecting their FR and PCFT cellular uptake, with 
little to no transport by RFC, and their potent inhibitions of GARFTase, the first folate-dependent 
step leading to the synthesis of IMP.153,237  Inhibition of de novo synthesis of purine nucleotides 
resulted in ATP depletion, leading to cytotoxicity and apoptosis.153,237   
In this report, our goal was to further establish a comprehensive SAR for the 5- versus 6-
substituted pyrrolo[2,3-d]pyrimidine ring system in relation to folate transporter specificity and 
inhibition of intracellular targets, based in part on findings of transporter promiscuity for 
PMX,198,204-207 and reports that PMX may in part derive its antitumor effects by inhibiting 
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AICARTase, resulting in accumulation of ZMP and activation of AMPK in addition to inhibiting 
TS. 145,146  Compared to the 6-substituted analogs, we found that the 5-substituted compounds in 
general: (i) were better substrates for RFC with the highest antiproliferative activities for 
compounds with 2-4 bridge carbons independent of the nature of the side chain ring system; (ii) 
were poorer substrates for PCFT with the exception of the 2-carbon bridge compound, PMX 
(AG125); and (iii) preserved FR cellular uptake, with the 4-carbon bridge analog AG127 showing 
the greatest FRα selectivity and potency in this expanded 5-substituted series of analogs without 
TS inhibitory activity.   
Compound AG127 was cytotoxic, as reflected in loss of clonogenicity in KB cells, and 
effected S-phase accumulation and apoptosis over 96 h.  Like its 6-substituted counterpart 
compound AG71,204 compound AG127 resulted in ATP depletion, although this appeared to be 
only partly due to inhibition of GARFTase.  Rather, a unique feature of the 5-substituted analog 
AG127 relates to its dual inhibition of both the GARFTase and AICARFTase reactions in de novo 
purine biosynthesis.  While PMX also inhibits GARFTase, the finding that the AICARFTase 
substrate ZMP accumulates in the presence of this drug suggested that GARFTase inhibition must 
be incomplete and that AICARFTase must also be a target as previously described, 145,146 although 
for PMX, total purine nucleotides, as reflected in ATP pools, were significantly preserved.  
Compound AG127, also inhibited AICARFTase, as reflected in incomplete protection in cell 
proliferation assays by AICA and demonstrated accumulation of the AICARFTase substrate ZMP, 
albeit less than for a comparable concentration of PMX. 
Previous studies suggested that AMPK activation secondary to ZMP accumulation and 
AICARFTase inhibition may result in inhibition of mTOR and contribute to the antitumor effects 
of high levels of PMX in the presence of thymidine.196,197  In the present study, we used KB human 
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tumor cells treated with PMX or with compound AG127.  In this LKB1-deficient tumor cell line, 
ZMP accumulation was accompanied by AMPK activation in the presence of PMX but not 
compound AG127.  Robust AMPK activation was also seen upon treatment with AICAR, or 
metformin.  However, ZMP accumulation and AMPK activation did not appear likely to contribute 
to the anti-proliferative effects of PMX in KB cells, as neither AICA nor metformin inhibited cell 
proliferation.  The antiproliferative and cytotoxic effects of compound AG127 toward KB cells 
must derive from a depletion of ATP pools, secondary to inhibition of both GARFTase and 
AICARFTase, rather than from activation of AMPK.  
In summary, a series of classical 5-substituted pyrrolo[2,3-d]pyrimidine antifolates 
AG124-AG129 were designed and synthesized as a hybrid of PMX and 6-substituted pyrrolo[2,3-
d]pyrimidines AG17, AG23, AG71 and AG94.  Compound AG127, the lead compound of this 
series, has an IC50 =12.7 nM against KB tumor cells in culture.  Rather than only targeting 
GARFTase, as with AG17 and AG23, both GARFTase and AICARFTase were identified as the 
intracellular targets of AG127.  The unique dual GARFTase and AICARFTase inhibition of 
compound AG127 makes it an excellent lead compound for further study including the design of 
additional antitumor analogs to optimize cellular folate uptake selectivity by FRs and inhibition of 
folate metabolizing enzymes, leading to a new generation of potent tumor-targeted agents.  The 
dual inhibition of both GARFTase and AICARFTase results in potent inhibition of purine 
biosynthesis and could preserve antitumor activity in the event that tumors become resistant due 
to alterations in one or the other targeted enzyme.  Such dual targeted inhibitors would seem to 
have substantial advantages over currently used agents that principally target only one intracellular 
enzyme target. 
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2.4 Materials and methods 
Reagents for biological studies.  [3’, 5’, 7-3H]MTX (20 Ci/mmol), [3’, 5’, 7, 9-3H] folic 
acid (25 Ci/mmol), and [14C(U)]-glycine (87mCi/mmol) were purchased from Moravek 
Biochemicals (Brea, CA).  Unlabeled folic acid was purchased from the Sigma Chemical Co. (St. 
Louis, MO). LCV [(6R,S) 5-formyl tetrahydrofolate] was provided by the Drug Development 
Branch, National Cancer Institute, Bethesda, MD.  The sources of the antifolate drugs were as 
follows: MTX, Drug Development Branch, National Cancer Institute (Bethesda, MD); and PMX 
(Alimta) (LC Laboratories, Woburn, MA).  Other chemicals were obtained from commercial 
sources in the highest available purity.  Novel antifolates (denoted by AG17-138 (see Table 
2.1))221 were synthesized by Dr. Aleem Gangjee and colleuges at Duequesne University, Pittsburg 
Pennsylvania. 
Cell culture.  MTXRIIOuaR2-4 (referred to as R2) is a RFC, PCFT and FRα null Chinese 
Hamster (CHO) cell line that was a gift from Dr. Wayne Flintoff (University of Western 
Ontario).321  From this parental cell line, RFC, PCFT and FRα were transfected in to give rise to 
isogenic CHO cell lines designated PC43-10 (expresses RFC but not PCFT or FRα), R2/PCFT4 
(expresses PCFT) and RT16 (expresses FRα).198,204-207,220,322  The CHO sublines were all 
maintained in α-minimal essential medium (α-MEM) supplemented with 5% penicillin-
streptomycin solution, 2 mM L-glutamate  and 10% heat-treated bovine calf serum (BCS) 
(Invitrogen).  Transfected cell lines were cultured in the presence of 1.5 mg/ml G418.  CHO cell 
lines were cultured prior to cell viability experiments in folate-free RPMI (FF-RPMI) (Invitrogen) 
with dialyzed fetal bovine serum (DFBS) (Invitrogen) supplemented with 5% penicillin-
streptomycin and L-glutamate.  Human FRα-expressing KB (nasopharyngeal) and IGROV-1 
101 
 
(ovarian) carcinoma cells were continuously maintained in FF-RPMI complete with 10% fetal 
bovine serum (FBS) and 5% penicillin-streptomycin and L-glutamate. 
Cell viability assays were performed exactly as previously described.198, 193-196  Cell lines 
were treated with a range of concentrations of standard or novel antifolates (0-1 μM), metformin 
(0-10 mM) or AICA (0-2 mM) in a 96 well plate with in FF-RPMI complete with DFBS, and 2 
nM (RT-16, KB, IGROV1) or 25 nM LCV (R2/PCFT4), penicillin –streptomycin and L-glutamate 
over a 96 h incubation period at 37◦C with 5% CO2.  To confirm FRα-mediated drug uptake and 
growth inhibition, 200 nM folic acid was added to the incubations with drug.  For proliferation 
assays with PC43-10 cells, cells were cultured in standard RPMI1640 with DFBS, penicillin-
streptomycin and L-glutamate for 96 h.  To quantitative viable cells, media was removed and Cell 
Titer-blue™ fluorescent reagent (Promega) was added.  Relative cell numbers were determined by 
relative fluorescence units measured with a fluorescence plate reader at 590 nm emission and 560 
nm excitation with Softmax Pro plate reader software.  IC50 values, corresponding to the drug 
concentrations that resulted in 50% loss of cell growth, were calculated from dose-response curves 
using Sigma Plot (v.12) software.  
In order to identify the targeted pathways/folate-dependent enzyme by the classic and 
targeted antifolates, proliferation assays were performed in the presence of adenosine (60 μM), 
thymidine (10 μM), or AICA hydrochloride (320 μM) and results compared to incubations in 
parallel without drug additions.198,205,220  
Colony forming assays were performed with compound AG127 to verify a cytotoxic (as 
opposed to cytostatic) response.  KB cells (~500) were plated in 60 mm dishes in FFRPMI/DFBS 
supplemented with 2 nM LCV for a 24 h incubation period at 37◦C in the presence of 5% CO2.  
Concentrations ranging from 0-10 μM of compound AG127 were added to media for an additional 
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24 h, after which the media was aspirated and replaced with FFRPMI/DFBS supplemented with 2 
nM LCV for 8-10 days.  To visualize colonies, the cells were washed (2x) with room temperature 
Dulbecco’s phosphate-buffered saline (PBS) (Sigma), followed by a wash of 5% trichloroactetic 
acid (TCA).  The TCA was removed, 10 mM borate buffer (pH 8.8) was added, followed by a 30 
min incubation with 1% methylene blue in borate buffer at room temperature.  The cells were was 
three times with borate buffer and the stained colonies were counted.  
Competitive MTX transport assays.  To determine if novel antifolates bound to RFC, 
reflecting membrane transport by this mechanism, competition with [3H]MTX for cellular uptake 
was measured in PC43-10 CHO cells.198,207  PC43-10 cells (~1.5x106 cells) were seeded in 60mm 
dishes.  After 48 h, cells were washed with PBS and uptake of [3H]MTX (0.5 μM) was measured 
in Hank’s Balanced Salts Solution for 2 minutes at 37◦C.  Cold (~4◦C) PBS was used to quench 
the reactions.  Cells were washed with ice-cold PBS (3X), then solubilized with 0.5N NaOH.  The 
cellular homogenates were assayed for radioactivity with a scintillation counter; protein 
concentrations were measured with Folin-phenol reagent.203  Levels of drug uptake were expressed 
as pmol/mg cell protein.  
FRα affinity binding assay.  To determine the binding affinity of novel antifolates to 
FRα,198 FRα-expressing  RT16 CHO cells (~1.5 x106) were seeded in a monolayer with complete 
α-MEM media.  Cells were washed with ice-cold PBS, followed by an cold acetate buffer (10 mM 
sodium acetate, 150 mM NaCl, pH 3.5) to release FRα-bound folates, then neutralized with ice-
cold Hepes-buffered saline (HBS) (20 mM Hepes, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2 , 5 
mM glucose, pH 7.4).  Cells were then incubated at 0◦C for 15 min in a cocktail containing [3’, 5’, 
7’,9- 3H]folic acid, in the absence or presence of unlabled folic acid or novel antifolate compounds 
(0-1 μM).  Cells were washed with cold HBS and solubilized with 0.5 N NaOH.  The cell 
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homogenates were collected and analyzed for radioactivity using a liquid scintillation counter.  
Protein concentrations were measured with the Folin-phenol reagent.  Bound [3H]folic acid was 
expressed as pmol/mg protein.  Using Sigma plot (v.12) software, dose-response curves were 
created and IC50’s were calculated.  Relative binding affinities were calculated as the inverse molar 
ratios of unlabeled ligands require to inhibit [3H]folic acid by 50% as determined graphically with 
Graphpad (v. 6.0) software.  By definition, the relative affinity of folic acid is 1.  
HPLC detection of ATP.  Intracellular ATP concentrations were determined using 
nucleotide extractions and an HPLC method, exactly as previously described.204,314  Briefly, KB 
cells were seeded in a T75 flask with FF-RPMI with 10% DFBS, 5% penicillin-streptomycin, 2 
mM L-glutamine and 2nM LCV.  Cells were treated with 1 µM of PMX, or compounds AG23, 
AG71, AG127 or AG136 for 24 h.  After the incubations cells were trypsinized and washed with 
cold PBS.  Nucleotide pools were fractionated on by reversed-phase HPLC on a C18 column for 
determination of ATP pools.    
Apoptosis and cell cycle analysis.  KB cells were treated with 1 µM of PMX of 
compounds AG23 or AG127  24, 48, 72 and 96 h in FF-RPMI media complete with 10% DFBS 
and 5% penicillin-streptomycin and 2 nM LCV.  Harvested cells were trypsinized and washed with 
cold PBS.  Samples were equally divided so cells could be stained with PI for cell cycle analysis 
and with Annexin V/7-AAD (Beckman) for apoptosis assays.  For cell cycle analysis, cells were 
fixed with cold ethanol (added drop-wise), then resuspended and stained in PBS containing 50 
µg/mL PI and 100 µg/mL RNAse (type I-A) (Sigma).  Cell populations were analyzed by flow 
cytometry and Flowjo software.  Flow cytometry and Flowjo software were also used to 
discriminate positively stained Annexin V/7-AAD populations including viable (annexin V and 7-
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AAD negative), early apoptotic (annexin V positive/ PI negative or 7-AAD low), and late 
apoptotic/necrotic (annexin V positive/PI positive or 7-AAD high). 
In situ GARFT inhibition assays.  To measure the extent of intracellular GARFT 
inhibition in the presence of antifolate inhibitors, we examined the metabolic incorporation of 
[14C(U)] glycine into [14C]formyl GAR (Figure 2.4) in the presence of azaserine.  Using 
previously published methods, 147,153-156,168,233  KB cells were seeded in complete media (above) 
and allowed to adhere to substratum for 24 h.  Cell were then washed with FF-RPMI, L- glutamine 
free with 10% DFBS, 5% penicillin-streptomycin and 2 nM LCV.  Cells were incubated at 37⁰C 
with 5% CO2 for 1 h with folate- and L-glutamine-depleted media containing 2 nM LCV, with and 
without PMX and compounds AG23, AG71, AG127, or AG136 (in DMSO) over a range of 
concentrations.  Control cells were treated with DMSO of equal volume.  Azaserine (4 µM final 
concentration) was added to the cells and allowed to incubate for 30 minutes.  This was followed 
by the addition of L-glutamine (2 mM) and [14C(U)]glycine (final specific activity 0.1 mCi/L).  
Cells were incubated 16 h.  Cells were washed with ice-cold PBS, trypsinized and collected.  Cells 
were washed with cold PBS, then treated with 5% TCA at 0⁰C.  Samples were centrifuged (4oC, 
14,000 rpm) and the protein precipitants were solubilized with 0.5 N NaOH for quantitation of 
protein concentrations with the Folin-phenol protein method.323  The supernatants were collected 
and extracted with cold ether.  After evaporation of ether, the remaining aqueous layer was gravity 
filtered through a 1 cm polypropylene chromatography column (Bio-rad) of AG1x8 (chloride 
form).  The columns were washed with 10 mL 0.5 N formic acid, followed by 4 N formic acid (10 
ml), and finally eluted with 8 ml of 1 N HCL collected in 8 fractions.  The eluate was measured 
for radioactivity and based on the percentages of radioactivity in the [14C]formyl GAR and non-
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specific radioactivity, the results calculated as pmol/mg protein.  Data were graphed using 
Sigmaplot (v.12) and IC50 were calculated. 
HPLC detection of ZMP pools.  Methods for detecting ZMP in KB cells treated with 
drugs were based on those described by Rascanelli et al.196  Briefly, KB cells were treated with 
assorted drugs (PMX, compound AG127 or drug free) for 48 h in FF-RPMI with 10% DFBS, 5% 
penicillin-streptomycin, 2 mM L-glutamine, and 2 nM LCV.  Cells were washed with PBS, treated 
with ice-cold 5% TCA and proteins were precipitated by centrifugation (1600 rpm, 10 min).  The 
soluble fractions were extracted with ether (2x) and fractionated by ion-exchange HPLC on a SAX 
250 x 2 mm column (Phenomenex) with a linear gradient from 5 mM NH4H2PO4 (pH 2.8) to 750 
mM NH4H2PO4 (pH 3.9) over 25 min at a flow rate of 0.2 mL/min.  Absorbance was monitored at 
280 nm and the intracellular ZMP concentrations were established by fitting the peak absorbances 
to a standard curve with commercial ZMP.  AraCMP was used as an internal control.  
Western blot analysis.  KB cells were treated for 48 h with PMX or compound AG127 in 
the presence of thymidine (5.6 µM).  Controls include vehicle control (water or DMS0; results 
were identical), or known activators of AMPK including metformin (10 mM), AICA (320 µM or 
1 mM), or AICA ribonucleoside (1 mM).  Cells were washed, suspended in 10 mM Tris-HCl (pH 
7.0) plus proteolytic and phosphatase (Phosphostop) inhibitors (Roche Applied Science) and 
disrupted by sonication.  Samples were centrifuged (14,000 rpm, 10 min) and 90 µg protein 
fractionated by SDS polyacrylamide gel electrophoresis on Laemmli gradient gels (4-20%).324  
Proteins were electrotransferred to polyvinylidene difluoride (PVDF) membranes (Pierce).325  
Detection of immunoreactive AMPK was with rabbit total and phospho-AMPK antibodies (Cell 
Signaling) and IRDye800-conjugated secondary anti-rabbit antibody (LI-COR, Lincoln, NE) 
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using an Odyssey® infrared imaging system (LI-COR, Lincoln, NE).  β actin was detected with 
anti-β actin mouse antibody and IRDye800-conjugated secondary anti-mouse antibody (LI-COR). 
 
  
107 
 
CHAPTER 3: DISCUSSION 
We are upon a major paradigm shift that has altered our view of ovarian cancer.  With this 
shift in thinking, changing the strategies in how we treat this disease is not only appropriate but 
the next logical step in disease intervention.  Currently, the treatment of this disease remains 
unaltered from the standard agents, irrespective of the diverse molecular biology of the tumor.  The 
identified molecular markers should be used to determine appropriate targeted therapy to address 
the driving oncogenic mechanism of the tumor.  Armed with the knowledge of the precise 
molecular pathways involved in the 2 categories of EOC (type I and type II), we can customize 
and design novel therapeutic strategies that may prove to be more beneficial than the non-specific 
chemotherapy that is currently in use. 
Combination therapy has proven to be effective in the treatment of many malignancies.326  
Mathematical models predict that combination therapy will be more successful at disease 
eradication than single agent or adjuvant treatment because combination treatment is more likely 
to prevent drug resistance.327  A treatment with a reduced propensity to drug resistance is highly 
desirable in ovarian cancer, as the recurrent drug resistant tumors are difficult to treat and are 
principally responsible for the patient’s demise.328  A recent study examined the effectiveness of 
combining PMX with simvastatin ( a statin) in mesothelioma and lung cancers and reported an 
enhanced apoptotic response with combination treatment than with single agent therapy.329  There 
is a heighten interest in the use of statins as anticancer agents which stems from their ability to 
disrupt the mevalonate pathway.329-335 This pathway has been associated with cell signaling, cell-
cycle progression, protein synthesis and membrane integrity.330 This study may serve as a platform 
to encourage more studies examining the effectiveness of antifolates in conjunction with other well 
established anticancer therapies (in addition to statins which are currently in their experimental 
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infancy as antineoplastics) that possess a different mechanism of action.  Combination therapy 
may have great significance in malignancies like ovarian cancers that harbor a number of mutations 
in kinases, GTPases and receptors for which there are experimental and well establish targeted 
therapies.  For example a FRα targeted therapy may pair with inhibitors of AKT, K-RAS, or HER2, 
as many ovarian tumors have activating mutations or overexpression of these kinases GTPases and 
receptors.336 
Overwhelming evidence suggests that FRα confers a growth advantage to malignant 
cells.60,62,128,174  There is speculation that the use of DNA damaging agents, like platinum-based 
therapies, may enhance FRα expression to increase intracellular folate levels to  encourage an up 
regulation of  nucleotide production to assist in DNA repair to address drug induced damage.263  
These identified molecular events in ovarian cancer offer an opportunity for the continued growth 
of the next generation of FRα-targeted treatments.  To date, classic antifolates have not made a 
notable appearance in the treatment of ovarian cancer.  In light of the enhanced expression of FRα 
driven by the use DNA damaging agents, like those used in ovarian cancer, FRα targeted 
antifolates can be useful as a second line therapeutic in this disease.  PMX, which shows some 
affinity to FR is currently being evaluated as a treatment option in platinum resistant ovarian 
cancer.337,338 
3.1 Targeting the AMPK/mTOR pathway 
We have characterized a novel class of agents that are effective against a cell culture model 
of HGSC, endometroid carcinoma and clear cell carcinoma.  Prior to obtaining crystallographic 
information pertaining to FRα, rational drug design aided in determining structural elements 
required for FRα-mediated drug uptake.  One unique feature of the agents under investigation is 
their ability to act as dual inhibitors of GARFTase and AICARFTase.  This ability to inhibit 
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AICARFTase, led to an accumulation of a purine intermediate (ZMP) but not AMPK activation.  
Therefore this study also allowed us to review the potential significance of AMPK activation in 
ovarian tumors and the potential of indirectly targeting AMPK and mTOR signaling for therapeutic 
advantage.  In recent years, AMPK-targeting in cancer treatment has become en vogue.  Much of 
its popularity can be attributed to the antidiabetics metformin and phenformin and their association 
with antitumor activity and reports suggesting that type 2 diabetics taking metformin had better 
cancer treatment outcomes than those taking other antidiabetics.339  While there has been much 
excitement surrounding the antitumor effects metformin has displayed in breast and ovarian cancer 
studies, the mechanism of action of this drug remains unclear.339-346  Most of this uncertainty arises 
from metformin’s ability to induce these antiproliferative and anti-tumor effects in an AMPK-
dependent or -independent manner.345,347  This leaves one to question if the effect on the cellular 
energy balance (AMPK/mTOR) has greater impact on cell viability than the antidiabetic is 
affecting the insulin metabolism of the tumor which is causing growth suppression and or 
apoptosis. 
There are a number of studies that imply that AMPK activation may assist in the survival 
and growth of select tumors (e.g., prostate cancer) through the activation of macroautophagy, 
which in certain cellular contexts can lead to cell death or cell survival.348  Autophagy is a common 
pathway for cell survival in many malignancies.  The modulation of macroautophagy in autophagy 
competent cells may result in no significant consequence for such cells.  A recent study showed 
that an apoptotic response to pemetrexed in combination with simvastatin can be enhanced in 
MPM and lung cancer cells when autophagy is inhibited.332  This demonstrates that autophagy 
inhibition can be an effective strategy to further potentiate cell death.  In the case where FRα is the 
sole means of drug transport, the method in which autophagy is inhibited becomes critical.  Folate 
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receptors require acidification of the lysosome to release substrate.  Many pharmacologic tools 
used to inhibit autophagy involve agents that prevent acidification of lysosomes and similar 
organelles, thus also making FRα-mediated uptake ineffective.  ATG siRNAs are useful molecular 
tools in an experimental setting; however, the use of such tools in a clinical setting, to date, may 
be impractical.  With the growing number of chemotherapeutics that are now being identified as 
AMPK activators, a closer examination of the effects of this activation should be conducted on the 
tumor of question prior to the selection of therapy.   
3.2 Targeting AICARFTase 
This study sought to describe the significance of AICARFTase inhibition in de novo purine 
synthesis in FRα-positive tumor cells.  Eukaryotic AICARFTase is a bifunctional protein that 
participates in formylation and cyclization to produce the purine precursor molecule IMP.349-352  
Like GARFTase, AICARFTase is a critical player in the de novo production of purine nucleotides 
and therefore has been suggested as a viable target to disrupt the purine biosynthetic pathway.  
Although both GARFTase and AICARFTase are transformylases in the same pathway and can use 
the same folate co-factor to perform their activities, they share no sequence homology.351,353  This 
divergence in sequence would make a drug directed to target one enzyme highly unlikely to behave 
as a substrate for the other.351  For this reason, MTAs like MTX (primary target DHFR)and PMX 
(primary target TS) are rather unique because they can inhibit both enzymes.349   
There are no known clinically investigated antifolates that primarily target AICARFTase.  
Burroughs and Wellcome designed and produced two antifolates, BW1540 and BW2315, to 
selectively target AICARFTase.  These two novel agents are sulfamido bridged 5,8 dideazafolate 
analogs, that were designed to create a stronger interaction between the protein and the small 
molecule.351  Both analogs were reported to exhibit strong inhibition towards AICARFTase 
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(BW1540, 8nM; BW2315, 6nM) as well as antitumor activity against human colon cancer cells ( 
BW1540 0.7-3.0µM; BW2315 1.0-5.0µM).351  Other non-folate based AICARFTase inhibitors, 
326203-A (2, -[5 hydroxy-3-methyl-1-1(2 methyl-4-sulfophenyl0-H-pyrazol)-4 sulfo-benzoic 
acid) have been explored, however none of these novel analog have progressed to clinical 
studies.353 
Experiments performed by the Moran lab with PMX prompted our own investigation using 
5-substituted pyrrolo[2,3-d]pyrimidines that indirectly suggested inhibition of the enzyme.  Direct 
quantitation of enzyme inhibition may help to elucidate a role in AICARFTase targeting for the 
disruption of de novo purine synthesis.  Using the structural information for both FRα and the 
AICARFTase enzyme may bring us closer to designing an FR directed inhibitor. 
This body of work includes the characterization of novel potent 5- and 6-substituted pyrrolo 
[2,3-d] pyrimidines that are effective against in vitro model of HGSC, endometroid carcinoma and 
clear cell carcinoma (IGROV-1).  Approximately 90% of advanced stage ovarian cancers are 
HGSC as this subtype generally presents at an advanced stage.232,247  Patients who present in stages 
III-IV have a 5 year survival rate of 15-30% and generally succumb to complications associated 
with this disease.  The grim statistics of ovarian cancer prompt the clinical development of highly 
potent compounds with reduced toxicity to allow for treatment at longer intervals to achieve 
maximum efficacy.  We can learn from the failure of the folic acid-conjugated toxin, vintafolide, 
and design improved folate-based cytotoxins akin to the novel compounds outlined in the study.   
The novel compounds examined in these studies are excellent candidates for further 
development.  Pharmacokinetic data and orthotropic mouse models of EOC may enhance and aid 
in greater support of these analogs as lead compound for more extensive pre-clinical and clinical 
investigations.  All together, we have developed agents with tumor selectivity based on an inherent 
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loss of purine salvage abilities due to the deletion of MTAP and their overexpression of FRα.  FRα-
positive tumors treated with novel 6- substituted pyrrolo[2,3-d]pyrimidines will undergo cell death 
due to purine nucleotide depletion via GARFTase inhibition.  Such depletion results in a reduction 
of cellular ATP pools, an induction of cell cycle arrest and eventually apoptosis.  The 5- substituted 
pyrrolo[2,3-d]pyrimidines share the unique characteristic of acting as a dual inhibitor of both 
AICARFtase and GARFTase, albeit the potency of inhibition towards GARFTase is reduced.  
While the 5-substituted analogs were able to induce ATP depletion, cell cycle aberrations and 
apoptosis, despite ZMP accumulation (likely resulting from AICARFTase inhibition) they were 
unable to activate AMPK.  The accumulation of ZMP alone, independent of AMPK activation 
may have been sufficient to initiate a cytotoxic response.  There are a number of studies that 
suggest that ZMP is a toxic metabolite with many cellular targets in addition to AMPK.354-356  ZMP 
accumulation has been linked to mitochondrial distress, increased apoptosis in malignant cells in 
an AMPK-independent manner and a depletion in pyrimidine nucleotide pools.356  While 
substitution at the 5th position allows for the addition of an enzyme target, selective FRα-directed 
membrane transport is compromised and RFC-transport is acquired (Figure 3.1).  These studies 
highlight the SAR of novel pyrrolo[2,3-d]pyrimidine antifolates .  The success of PMX and the 
expansion of its therapeutic range beyond lung cancer, warrants further investigation of novel 
pyrrolo[2,3-d]pyrimidine antifolates.  Using structure based drug design that incorporates the 
recently discovered crystal structure of FRα along with the structural information of AICARFTase, 
we will perhaps come closer to designing a potent FRα targeted AICARFTase inhibitor to provide 
a less toxic, yet efficacious treatment option for  ovarian cancer. 
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Figure 3.1: “Big picture” schematic:  The following schematic highlight the key concepts in this 
body of work.  
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ABSTRACT 
THE THERAPEUTIC TARGETING OF FOLATE RECPTOR ALPHA POSITIVE 
TUMORS VIA FOLATE RECEPTOR-SELECTIVE NOVEL 5-AND 6- SUBSTITUTED 
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Ovarian Cancer is the fifth leading cause of cancer-related death of women in the United 
States.  Epithelial Ovarian Cancer (EOC) constitutes 85-90% of malignancies within the ovary, 
with an alarming majority of these cases diagnosed at advanced stage.  While most patients are 
initially highly responsive to the current treatment standard, there is a very high probability that 
they will recur with a drug resistant fatal disease.  Currently there is no validated comprehensive 
model of disease progression for ovarian cancer, although tremendous progress has been made in 
understanding the origin of this disease and a putative precursor lesion has been identified via 
molecular profiling.  This progress has led to the identification of molecular signatures that not 
only distinguish high grade from low grade tumors, but it also highlights mutations that are unique 
to each histological type.  Even though we are armed with this information and are well within the 
age of molecular targeting, the treatment of ovarian cancer has remained the same for over 40 
years, when the use of platinum-based therapies and taxanes were introduced. 
Approximately 90 percent of EOC are folate receptor alpha (FRα) positive with the extent 
of receptor over-expression corresponding with stage and grade of disease.  FRα based therapies 
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are a subject of increasing interest warranted by a growing number malignancies, from various 
tissue types, showing FRα expression.  Due to this increase of receptor expression in advanced 
disease in EOC, designing FRα-targeted agents will enhance the therapeutic window in a 
population of patients where most treatments fail.  The clinically approved antifolates, 
methotrexate (MTX) and pemetrexed (PMX), have greatly improved treatment outcomes in a 
number of malignancies, however they have been implicated in dose-limiting toxicities that are 
thought to arise from uptake mediated by the ubiquitously express protein, the reduced folate 
carrier (RFC).  This encourages the development of novel antifolates that utilize other available 
folate transport mechanisms over RFC.  
In this study we explored the impact of the addition of various structural components on a 
pyrrolo[2,3-d]pyrimidine scaffold and demonstrated: (1) the significance of a 5 vs 6 position 
substitution on the scaffold and how it impacts the pharmacology of the compound; (2) that novel 
6-substituted pyrrolo[2,3-d]pyrimidines show remarkable potencies that are mediated via FRα 
membrane transport; and (3) the impact of purine salvage on the efficacy of novel antifolates. 
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